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Abstract 
Bayesian Networks (BNs) have been considered as a potentially useful technique in the 
health service domain since they were invented. Many authors have presented BNs for 
managing health care and waiting time, predicting outcomes, improving treatment 
recommendation process and many more. Despite all these development effort, BNs 
have been rarely applied to provide support in any of these clinical areas. This thesis 
investigates the use of BNs for analysing clinical evidence data from observational 
studies, currently considered the type of study proving the weakest evidence.  
It begins by investigating challenges around the analysis of data and evidence faced by 
health professionals in health service. It then discusses the importance of observational 
studies to understand how disease, treatments and other clinical factors interact with 
each other. Further it describes the various techniques, such as using statistical inference 
methods and clinical judgements, available to justify any discovered interactions. In 
contrary to Frequentist approaches, Bayesian Networks can combine knowledge and 
data to derive evidence of relationships between different factors.  
This thesis proposes a novel way to combine knowledge and observational data in 
Bayesian Networks to derive evidence for clinical queries. Firstly, it shows how to 
construct and refine a Bayesian Network model by performing hypothesis tests to check 
which out of a number of experts’ judged causal relations between a set of domain 
variables are plausible for the available observational data. Secondly, it proposes 
techniques to evaluate the strength of all plausible relations/associations. Finally, it 
shows how these techniques are combined into a novel data analysis method for 
answering clinical queries by combining knowledge with data. In order to illustrate this 
method this thesis uses a case study and data about the operation of a multidisciplinary 
team (MDT) that provided treatment recommendations to cancer patients, at Barts and 
the London HPB Centre over five years. In summary, the case study shows the potential 
for the method and allows us to propose ways to present results in a comprehensible 
format. 
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Chapter 1 
Introduction 
Clinicians and other health care professionals use research studies to understand the 
domain. The design of a study is considered to be crucial for determining the strength of 
the evidence resulting of the study. Experimental studies such as randomised controlled 
trials (RCTs) use randomisation to decrease the effect of confounding, and provide the 
highest ranked evidence. Due to this most attention has been given to experimental 
trials rather than observational studies. However, experimental trials are not suitable for 
all questions of interest, and in addition, are sometime impossible to conduct since the 
time and cost require are often very high. Thus, an important research challenge within 
the health service domain for today is to produce strong evidence from observational 
studies.  
Every study uses a technique for assessing the strength of the results that it generates. 
For observational studies, two common techniques are: using P values, and Confidence 
Intervals. Both these statistics state if the result derived from the hypothesis tests it is 
statistically significant. Some judgments are then made by experts to determine how 
likely a change can be made on the basis of this evidence. This process can become 
difficult since studies reporting these measures rarely indicate how they should assist in 
managing complex issues.  
The analysis of observational data requires the use of a model, such as a multivariate 
regression. Bayesian networks (BNs) are well known as expert systems but can also be 
used to model data. A BN is a probabilistic model that represents the probabilistic 
relationships and conditional dependencies among variables. A BN allows probabilistic 
inference to be performed coherently, using the law of probability. Also a BN has the 
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capability to represent associations elicited from experts as well as from data, and this 
makes it perfectly suitable for causal modelling. 
Many BNs have been developed to provide support to various clinical tasks including 
diagnosis, treatment selection, risk analysis and health care management 
[3][4][5][6][7][8]. However, their application to regular practice is still rare. Numerous 
studies have mentioned the existing methods for justifying the use of BNs appeared to 
have drawbacks [9][10]. Specifically, these methods are mostly for showing how 
accurate a BN model is in predicting the states of one outcome whereas in most health 
care domain the existing framework of clinical evidence from observed data is for 
providing decision support to queries regarding multiple outcomes.  This thesis 
proposes a novel way to use a BN model to address clinical queries. . The initial interest 
here is to form a BN model for representing causal relations by combining the 
knowledge of experts and data found from an observational study.  
Unlike most approaches, there is no need to construct a full model, instead the relations 
for each variable can be considered in turn to establish if the knowledge based causal 
relation show the plausibility of existence for the available data. Secondly, this thesis 
proposes to use the data of plausible relations of the BN model for assessing the 
strength of each of these relations. Further, it demonstrates that Bayesian analyses on 
findings from this assessment generate evidence, allowing more confident support for 
queries by health professionals. 
The method is introduced using a case study and data collected from meetings of a 
Multidisciplinary Team (MDT) meeting process that treats patients suffering with 
cancer or suspected to have cancer. Data about the MDT meeting process were collected 
from the Barts and the London HPB (HepatoPancreaticoBiliary) centre following some 
changes to the MDT process. By evaluating the strength of each of the associations, we 
examine whether the MDT process has improved treatment recommendations for these 
patients.  
 
. 
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1.1   Hypothesis 
The thesis is about using a BN to combine the use of both knowledge and data to 
answers clinical queries. In particular, the thesis addresses the five research hypotheses 
listed in Table 1-1. 
 
  Table 1-1 Research hypotheses verified in this thesis 
Hypothesis Chapter of 
the thesis 
It is important and possible to answer clinical queries from 
observational data. 
 
It is important to propose a new method for answering clinical queries 
that derive from observational studies. 
2, 3, 4 
Data, if available, can demonstrate existence of associations in an 
expert constructed causal Bayesian Network model 
6 
Using both the knowledge of experts and data from an observational 
study we can form a BN to represent associations between its variables. 
5, 6 
For the BN model we can assess the strength of each association. The 
results from this assessment can then help to address a relevant query 
with confidence. 
7 
The above techniques have the potential for successfully analysing 
observational data found outside the clinical domain  
8 
 
1.2   Structure of this thesis 
Chapter 2 discusses the potential benefits of Bayesian methods for introducing new 
changes in health service. We review the existing approaches to examine the 
effectiveness of complex health care initiatives and discuss the pitfalls of these 
approaches.   
Chapter 3 introduces BNs and reviews existing methods for their construction, 
including both expert judgement and learning from data. The importance of dynamic 
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discretisation which extends the use of BNs to continuous variables is described. Then, 
the chapter highlights existing techniques to complete a BN’s construction process.  
Chapter 4 reports on the existing applications of BNs to medical and health care 
domain.  The chapter surveys the types of application in the health care domain and the 
associated techniques of evaluation and their limitations. Overall, this survey shows that 
the existing techniques for using BNs in this domain are not sufficient for our aim: the 
analysis of non-experimental data. 
Chapter 5 introduces the case study. The chapter identifies the factors relevant for the 
problem domain, including the assumptions that a health professional might wish to 
confirm. Then, drawing on existing work, it presents an initial BN for the domain that 
was constructed by consulting with an expert. This BN contains causal relations and is 
the starting point of our analysis. 
The next three chapters present the main contribution of the thesis.  
Chapter 6, working with the case study shows how the expert-judged causal relations in 
the initial BN can be assessed against data, and the results can be used to ensure that the 
structure of the BN model given in Chapter 5 represents only those associations that 
both experts and data have confirmed. 
Chapter 7, again using the case study, shows how to assess the strength of each expert 
and data based association of the BN model and to use the results to address queries. 
The chapter shows how to construct the posterior distribution over the parameters of 
each association from data, using an auxiliary multinomial BN model. Further, it shows 
how this model can be used to answer questions about the modelled domain, using a 
Bayesian approach to uncertainty and confidence. 
Chapter 8 presents the complete methodology for the analysis of data, in a way that 
could be applied to other studies. The chapter shows that the approach is not restricted 
to the domain of the case study used but can be applied to successfully model 
associations in any domain. 
Chapter 9 provides concluding remarks of this thesis. 
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Chapter 2 
Clinical Evidence in Health Services  
Introducing changes in health service is a challenging task. It takes time, collaborative 
effort and energy. Before implementation it is essential to ensure that this change is in 
the best interest of patients, will improve the quality of care, clinically-led and based on 
the best available clinical evidence. Many health professionals now seek knowledge 
from scientific research to make their decisions on organisational design. Marston et al. 
categorised these studies into six study types: descriptive, taxonomic, analytics, 
interpretive, explanatory, and evaluative [11].  
In evidence-based approach, the best way to assess the effect of an intervention is to 
perform a randomized controlled trial [12]. When the change in health service concerns 
introducing a complex intervention such a multidisciplinary team which varies in 
composition, frequency, and processes, this is difficult to conduct [13]. In [12] Boxer et 
al compared the intervention group with a non intervention group to evaluate the 
performance of such an intervention, and acknowledged that the approach generates 
bias. 
Identifying factors which impact on intervention effectiveness and understanding 
possible disadvantages of the intervention is also not simple from research studies. 
Altman [14] stated that a large proportion of published medical research lacking either 
relevance or sufficient methodological rigour to be reliable enough to answer clinical 
questions. Classical measures showing associations between factors such as P-values 
and Confidence Interval (CI) values are hard to interpret [15][16][17].  In contrast, 
Bayesian inference is advantageous since it allows expertise, or prior evidence, to be 
integrated with evidence from data. 
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In this study we examine the potential benefits of Bayesian methods for introducing 
new changes in health service. We review the existing approaches to examine the 
effectiveness of complex health care initiatives and discuss the pitfalls of these 
approaches.   
2.1   Introducing organisational changes in 
health services 
In health services managers and health professionals regularly take challenging 
initiatives to make useful organisational changes. For patients suffering with complex 
illness such as cancer and mental illness, many have focused on replacing existing 
recommendation process with Multidisciplinary Team (MDT) Meetings intervention.  
 
What is an MDT? 
MDT is the short word for ‘multidisciplinary team’. The key idea of an MDT is that 
different hospital specialists work together to provide care for a patient. In each MDT 
meeting the team discuss patients and make decisions about the next stage of their care 
[18].  
A patient journey in the MDT arm 
For a complex disease like cancer GP refers the patient to a clinic/hospital. During the 
clinic visit specialists examine symptoms, test results and other relevant factors to 
understand the current state of the disease. After diagnosis, the patient is discussed at an 
MDT meeting where doctors, specialist nurses, the oncologists, surgeons, radiologists 
and pathologists meet to discuss the specific case, and consider the scans, general health 
of the patient, the type of the cancer and the wishes of the patient to decide an 
appropriate course of treatment. 
What is involved in the non-MDT process? 
In a non-multidisciplinary setting a GP can provide health care to patients. Figure 2-1 
provides a simplified overview of the pathways followed in general practice to provide 
effective treatments to patients.  
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In brief, after seeing a patient presenting with signs and symptoms, a GP may follow (a) 
the history of the patient, (b) any presented complain, (c) the outcomes of test(s), or (d) 
all listed options for diagnosis. The GP applies the diagnostic label to justify a decision 
to prescribe a treatment option. If no treatment is needed then the GP may discharge the 
patient or sent him back home to monitor. For a complex diagnostic label, the GP may 
decide to refer the case to a specialist in a hospital. This referral often initiates the MDT 
process for recommendations. 
 
 
Figure 2-1  A non MDT process 
Evaluating the impact of MDT 
As MDT meetings require substantial administrative, human and technical resources to 
run successfully, it is important for the meetings to run well[19]. The following 
questions can therefore be used for evaluating MDT meetings: 
 
! How long does it take to discuss each patient? 
! At how many meetings is each patient discussed? 
Patient'
GP#
Diagnosis 
Treatment Monitor Discharge 
Outcome 
Referral 
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! Is the decision correct? 
In [12] Boxer et al compared MDT and non MDT groups patients to understand the 
pattern of care for those suffering with lung cancer and reported decreased diagnosis to 
surgery time, more recommendations of radiotherapy (66% versus 33%, P <0.001), 
chemotherapy (46% versus 29%, P < 0.001), and palliative care (66% versus 53%, P < 
0.001). In [20] authors reported better treatment recommendations in the MDT group 
(76.81% patients underwent neoadjuvant chemotherapy instead of direct surgery). In 
[21] the use of a multidisciplinary breast cancer evaluation programme provided 
important second opinions for many and  led to a change in treatment recommendation 
for 43% (32 of 75) of the patients. In [22] authors compared the treatment of patients 
with inoperable NSCLC before and after the introduction of MDT, and found that the 
introduction of an MDT was associated with an increase in the proportion of patients 
being staged and a change in treatment; more patients received chemotherapy and fewer 
received palliative care only. 
 
In addition to the benefits in treatment recommendations, MDT discussion can facilitate 
faster initial of treatment [23], reduce hospitalisation time and costs [24][25], and 
improve coordination of care[26]. Many authors have shown that patients who received 
multidisciplinary care were significantly more satisfied than others [27][28]. Also in 
most situations patients prefer to visit once to a clinic and receive care provided by a 
team of specialists then a multiple-visit approach [23]. 
 
A number of the above studies are based on before and after design [29]. Since care for 
cancer patients is improving over time, it may be possible that patents for recent times 
were staged more accurately than those diagnosed before [12]. Some MDT related 
research studies have shown the benefits of MDT meetings by conducting multiple 
concurrent organisational changes such as centralising the process [30], increasing 
caseload [31], and appointing new specialists [32]. Despite these adjustments the 
evidence for implementing an MDT process is compelling. The question of ones interest 
is now how to implement this process change and this is what addressed in the empirical 
part of the thesis.  
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2.2 Causality 
The term causality is about investigating that a cause is something that produces an 
effect. For the time-series data in Economics, Grenge [33] formulated causality as this - 
a ‘cause’ ought to improve our ability to predict an effect in a probabilistic system. In 
this discipline the use of structural equation models has been seen as the dominant 
approach to making inference about causal effects. An example of causality from 
Medicine is that the establishment of specific bacteria is the cause of specific infectious 
diseases. In Statistics a probabilistic cause is one that increases or reduces the chance 
that the effect will occur, and a probabilistic statement about a cause and effect gives 
quantitative information about an estimate of the strength and nature of that relation. It 
also provides quantitative information on potential effect modification and about any 
relation that may exist between the cause and its effect [34]. 
 
Experimental studies, such as Randomised Controlled Trials (RCTs) often provide the 
most trustworthy methods for establishing causal relations from data. In an 
experimental study (a) the analysis of causation begins with studying the effects of 
causes, (b) effects of causes are always relative to other causes – it takes two causes to 
an effect and (c) not everything is taken as a cause so focus is always on some specific 
fields. Such studies, while potentially highly informative, may be: 
• Impossible, impractical or unethical. For example, to assess the effectiveness 
of photodynamic therapy (PDT) it is impossible for the clinicians to allocate 
the patients with brain tumours into a PDT group and a placebo group [35].  
• Unnecessary if the effect of a treatment is very high.  For example, the use of 
Imatinib (Glivec) to treat patients with Chronic Myeloid Leukaemia [36].  
• Inadequate. In an RCT, the patients who participate must meet the chosen 
study criteria and the follow-up period is short, whereas the treatment 
evaluated takes place in clinical practice – where a large quantity of patients 
suffering from many different conditions are of concern – for a longer period 
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of time. Thus, the estimate of an effect of a treatment which was found in the 
RCT may not be externally valid or generalisable outside the context of the 
trial [37] [38].  
• Increases the type-1errors – false positive errors – due to interim analyses. 
During an ongoing experiment, an interim analysis of data is held to let the 
investigators know whether the intervention is efficient or harmful in relation 
to the current placebo in order for them to decide if the study should be 
stopped earlier than planned. In any situation, an interim analysis that is held 
but hasn’t been planned in advance increases the type-1 error [39]. 
Causality to nonrandomised observational studies has also been investigated 
extensively. Observational studies are based on observed data, and these data are more 
readily available than experimental data. As observational data become increasingly 
available, opportunities increases for using them. Besides, observed data describe 
situations that happened in the past and there are no needs for doing experiments. These 
make applications of observational studies higher where generalisation is an issue 
during discovery of causal relations or simply statistical associations. 
2.2.1    Causal DAG 
Directed acyclic graph (DAG) models are well-used tools for capturing causal 
relationships and for guiding attempts to discover these relations from data. They supply 
a means of extracting causal conclusions from probabilistic conditional independence 
properties inferred from purely observational data.  
A DAG consists of nodes that represent variables, and arrows that join these variables. 
Given a joint distribution over an ordered set of random variables (!! ,… ,!!), one can 
construct an associated DAG with the (!!) as vertices by adding arrows to !!!!(! =0, . . ,! − 1) from the smallest subset, !!, of all earlier variables, !! = !!,… ,!! , such 
that 
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!!!! !! |!! 
According to Hernan and Robins [40], a causal DAG is a DAG in which: 
i.   the lack of an arrow from !! to !! can be interpreted as the absence of a 
direct causal effect of !! on !! (relative to other variables on the graph) 
ii.    the inclusion of the measured variables implies that the causal DAG must 
also include unmeasured common causes. 
One description of the idea of 'cause' relates it to an intervention or forced changes. If A 
causes B, then forcing A to a new value causes B to change. This is relevant to decision 
making when there is a need to change B but it cannot be done directly. Pearl [41]and 
other have popularised causal modelling and have developed a principled way to predict 
the outcome of interventions. These models assume that the direction of causal relations 
is known from some source other than data.  
Also, with two variables A, B, it is not possible to tell from data (i.e. statistics) whether 
A causes B or B causes C or neither. The third cases arises from a possible unknown 
third variable U, which causes both A and B and therefore give rise to a correlation 
between A and B. 
2.3   Frequentist inference and interpretation 
In the frequentist method, an investigator performs a statistical test – e.g. a hypothesis 
test – on a sample of a target population and uses the results of the test to make 
inference about the population. The method mostly utilizes P-values and confidence 
intervals (CIs) to measure the results of the test. Because these measures are easy to 
misinterpret they can easily lead to an invalid conclusion when a clinician considers 
them to decide on clinical application [15]. I discuss about the use of the measures of 
frequentist more in Sections 2.3.1 and 2.3.2. In contrast to the frequentist method, the 
Bayesian methods of statistical inference are rather simple and highly applicable 
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alternative for assessing the results of statistical tests [42]. This method is described in 
Section 2.4.  
2.3.1    Null hypothesis, P-values and Confidence intervals  
The frequentist method uses hypothesis tests and considers the null hypothesis. For a 
hypothesis such as: is chemotherapy with surgery more effective as a treatment for the 
patients with stomach cancer than the chemotherapy alone, the null hypothesis,!!, 
particularly states: there is no difference in effect between the treatment options. An 
investigator tests a null hypothesis by calculating the P-value.  
There are many definitions available for a P-value.These definitions are placed in 
relation to either the test of significance of Ronald A. Fisher or the hypothesis testing 
method of Jerzy Neyman, and Egon S. Pearson. Here we have given two definitions to 
demonstrate the difference: 
 “The P-value is the probability of observing data as extreme as, or more 
extreme than, the data actually observed assuming that the null hypothesis is 
true”. [43] 
“A p-value is the probability of finding a result as extreme, or fantastic, or 
disappointing, as the one return by a statistical test”. [44]         
A P-value of 0.05 is the cut-off for rejecting or not rejecting the null hypothesis 
[45][46]. If the measured P-value of the test is below the cut-off it indicates that the 
result is statistically significant [47] – that is, considering the hypothesis above, any 
difference in effect between the treatment options is likely to be  real and not to have 
occurred by chance [48]. Conversely, a P-value which is equal or greater than 0.05 
informs the investigator that the evidence is not sufficient to reject the null hypothesis 
so the result of the test is not statistically significant and any difference may be due to 
chance. 
However, a P-value less than the cut-off point is not the evidence to support the 
hypothesis. According to Akobeng [45], a “p-value of <0.05 should not be regarded as 
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‘proof’ that an intervention is effective, and a p-value of ≥0.05 does not also mean that 
the intervention is not effective”. Further, the P-value does not give information about 
whether the result of the test is suitable to be placed into clinical practice. Many have 
therefore suggested that a study should use confidence intervals (CIs) to determine the 
clinical importance of the result [42]. There are now also requirement that to submit a 
clinical paper the authors must include both CIs with the P-values in their results 
[49][50]. 
A CI measures the significance of a result and the magnitude of effect of the 
intervention that is under consideration [42]. Instead of defining a probability, the CI 
estimates a range of plausible values within which the ‘true’ value is expected to be 
observed, and the use of the 95% CI, the measure that is most common in the studies, 
indicates that 95 out of 100 times the true value lies within the range [15]. The width of 
the CI can indicate (1) the precision of an estimate – the narrow the CI the better is the 
precision – and, (2) the amount of error in an estimate. 
As a method of reporting the statistical significance of results, CIs are known to be 
easier than a P-value.[45]. In brief, along with the information about the statistical 
significance, a CI helps an investigator to determine when an effect is clinically 
important [48] [51][52].  
2.3.2    Criticisms of the use of P-values and CIs 
The use of both P-values and CIs have been criticised for their improper use and 
misinterpretation with regards to the results of clinical research studies.  
In [53], Steven has stated twelve misconceptions that exist among investigators when 
they decide to interpret a P-value that arises from a two-group randomized controlled 
trial. Some of these misconceptions also exist among the investigators when they 
interpret the P-values that arise from an observational research study. Fenton and Neil 
[54] also present a summary of the problems with the use of P-values, drawing on the 
book The Cult of Statistical Significance [55]. This thesis includes some of the 
criticisms which the authors of the above studies have mentioned, and in addition, 
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included few more that other researchers have made during their discussion regarding 
the use of the P-values and CIs. 
Specifically, the following criticisms are found regarding the use of P-values: 
•    Provides misinterpreted assessment of the null hypothesis. 
If a P-value is 0.05, an investigator often misinterprets the result stating that there is a 
5% probability that the null hypothesis or no relation is true [56][57]. However, R.A 
Fisher has introduced the P-value as a rough numerical guide which one can follow to 
evaluate the strength of evidence against the null hypothesis. His proposal in relation to 
a P-value less than 0.05 was to suggest an investigator to repeat the test and make 
conclusions based on the results of subsequent tests. Besides, it is not possible to equate 
the P-value with the probability of the null hypothesis since an investigator only 
calculates the P-value considering that the null hypothesis is true [56]. 
•    Makes one to focus less on the problem of interests. 
A smaller P-value is only to show more evidence against a null hypothesis. But from an 
investigator’s point of view the exclusive focus on the null hypothesis is not always 
interesting [54]. Goodman [58] demonstrates that deriving the strongest evidence 
sometimes requires a different scope, addressing a question that needs a composite 
hypothesis in order to answer it properly. 
•    Generates confusion because the use of cut-off level is arbitrary. 
A P value of < 0.05 is commonly taken as statistically significant, but the use of this 
threshold for the P-value has been considered to be arbitrary [46][59]. For an 
investigator it is difficult to propose an interpretation of a P-value that is near to 0.05; it 
turns out that during an interpretation any previous evidence or the judgment influences 
the suggestion. For example, if a P-value is 0.06, the value is a short distance from the 
significant level and therefore, the investigator can suggest the interpretation that the P-
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value is showing is that the result is almost statistically significant or he can simply say 
that there is no evidence of a relation [42]. 
•    Accelerates inconclusive assessment of clinical relevance. 
The P-value does not provide the information that is more important to a clinician, 
namely, the clinical significance or relevance of a relation [54]. What clinicians are 
interested in is to know about the magnitude of an effect and therefore, they can 
intuitively misinterpret statistical significance as clinical significance. 
•    Provides wrong interpretation of the used data. 
“The P-value is not the probability of the observed data under the null (chance) 
hypothesis, because the P-value includes the probability of more extreme data”. [56] 
•    Provides misleading information for the tests of significance. 
Two tests based on the same observed data do not always give us the same P-value [58]. 
Goodman [56] has further demonstrated that if two trials are run, and the sizes of the 
trials are the opposite – one is large whereas the other is small, even if the P-values for 
both are 0.05 the evidence against the null hypothesis in these cases will be different. 
This tells us that an investigator’s assumption that the identical data means the identical 
evidence will not always be acceptable.  
•    Overemphasised on the use of the cut-off level. 
When interpreting the P-value the investigator’s emphasis on the 0.05 threshold value is 
regarded more strongly than it should be [60].  Since a P-value of 0.05 only corresponds 
to the minimum Bayes Factor (we will discuss more about Bayes Factor in Section 2.3) 
of 0.15, it represents at best moderate evidence against the null hypothesis. Sterne et al. 
[46] have mentioned that a strong evidence against the null hypothesis comes from a P-
value which is much smaller than 0.05.  
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•    Inappropriate for an inductive inference. 
The P-values represent deductive inference [42]; a hypothesis is initially held and tests 
are then performed to check if the observations are consistent with the hypothesis [61]. 
In contrast, strong association inference in clinical practice requires inductive inference 
where the clinicians first make observations and then decides which hypothesis is likely 
for the observations [62]. Since their interest is in knowing the probabilities of effects 
based on the observed data, the clinicians often incorrectly interpret P-values using 
inductive inference [61][63].     
•    Suitable only to support dichotomous outcome. 
The emphasis of a P-value is on the strength of evidence considering that only 
dichotomous ‘reject’ or ‘fail to reject’ outcomes. 
The criticisms made regarding the use of CIs are as follows: 
•    For the 95% CI, an investigator often interprets this to imply that there is a 95% 
probability that the true relation lies with the 95% CI [64].Whereas what 95% 
actually means is that when the same test is repeated many times and the CI is 
calculated for each, then 95% of such intervals will include the true relation 
[64], and many clinicians ignore this distinction during their interpretations. 
•    While making an interpretation, clinicians do not always consider the 
implications – the importance for applying into clinical practices – of the range 
of values in the interval [46]. They prefer to use CIs to examine significance and 
the 95% CI usually uses P < 0.05. A relation is classified as significant when the 
95% CI excludes the null hypothesis of no relation [15].  Regarding this 
drawback with CIs, Goodman [61] states “their impact on the interpretation of 
research is unclear”. 
•    Clinicians do not always prefer to make healthcare decisions with 95% 
confidence. Their interest in confidence can vary in relation to the effect of an 
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association between the factors. For example, a clinician may be interested in 
knowing whether an intervention has an 85% probability of showing an effect.  
•    The use of a CI can lead to a misleading conclusion. With the reference to the 
study [65] Shakespeare et al. [15] explained that the results given suggesting the 
effect is not being statistically significant, do not rule out a potential benefit 
completely and therefore that, a conclusion of ‘no effect’ is misleading.  
•    The relationship between the width of a CI and the sample size of the test is not 
always linear; in general, investigators need to increase the sample sizes by a 
factor of four to halve the width of the CIs [51]. Therefore, if a clinician 
intuitively thinks that a linear relation exists, erroneous decisions can result. 
2.4   Bayesian inference 
Bayesian inference method can overcome many limitations of the frequentist and offer 
many advantages when it comes to evaluating the strength of evidence. In particular, 
these advantages can be summarised by the following points: 
•   Bayesian inference calculates the evidence in favour of a null hypothesis 
[66][60][67]. 
The usual interpretation of significance tests can be used only to reject hypotheses and 
do not offer an assessment of the strength of evidence in favour of the null hypothesis. 
Bayesian methods of statistical inference let us calculate what is really required as 
evidence – including the cumulative impact of different evidence – and this is not !! ! !) but !! ! !) by using Bayes Theorem: 
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Here, !!(!) specifies the prior probability regarding the uncertainty for the hypothesis 
and ! ! !) is the likelihood of data which specifies the probability of the data given 
the hypothesis. These two then combine in Bayes’ Theorem to give ! ! !) which is 
the posterior probability of the hypothesis given the observation that is made from the 
data. 
•    It can handle uncertainty in moeling and draw inference about a relation. 
While investigating the effect of one variable on another one needs to think about 
several other possible covariates. It is not often clear if the chosen set is the right set of 
covariates, and this confusion generates uncertainty that should be taken into account 
during this investigation. Similarly, other functional and distributional assumptions may 
lead to different estimates of quantities of interest, and again, one would like to take 
account of uncertainty about these assumptions within the estimation process. The 
Bayesian inference method allows doing this in a natural way by averaging over the 
candidate models with their posterior probabilities as weights [66][57][68].  
•    By giving the probability for a hypothesis on the basis of the data Bayesian 
methods permit inductive inference, which are more appropriate for assessing 
cause-effect relations. [62][69]. 
•   During hypothesis tests, the use of Bayesian methods enable a researcher to 
measure the strength of the evidence by calculating Bayes factors (BFs) 
[56][61][70].  
A Bayes Factor (BF) is the ratio of the probabilities of two competing hypotheses. For 
example, if we have two hypotheses:! ! and !!, the BF computes by taking the ratio of 
the conditional probability of the hypothesis, !!, given the data ! and the conditional 
probability of the competing hypothesis, !!, given the same data !!, from the equation 
as follows:  
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When the priors for the hypotheses – ! !!  and !(!!) – are equal, the Bayes factor of 
two competing hypotheses is 
 
In words, 
Posterior odds = Bayes factor × prior odds 
The use of Bayes factor can quantify the evidence for one hypothesis relative to another 
[71] and can suggest which hypothesis is better for predicting the data that an 
investigator observes. According to Goodman [58], the use of Bayes factors lets the 
investigator make a clearer distinction between evidence and error, and enables him to 
derive a proper measure for the evidence. The magnitude of the Bayes factor calculated 
from the observed data also informs us about the strength of the evidence [56]. For this 
purpose, Jeffreys [72] has recommended a scale (Table 2-1); an interpretation of the 
Bayes factor based on the scale helps to decide whether the data we have to hand 
support one hypothesis over another and in what degree. 
Table 2-1 Jefferys’ scale of evidence for Bayes factors 
Bayes factor Strength of Evidence 
>       100 Decisive evidence for !! 
30        -       100 Very Strong evidence for !! 
10        -         30 Strong evidence for !! 
  3        -         10 Substantial evidence for !! 
  1        -           3 Anecdotal evidence for !! 
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 According to the scale, if the Bayes factor for !! against  !! is 1.5, and then the 
interpretation indicates that the observed data are 1.5 times likely to have occurred 
under the hypothesis !! than under the hypothesis  !! . This BF corresponds to the 
category: Anecdotal evidence for! !, which specifies that although the BF favours 
the hypothesis! !, we do not have strong evidence from the observed data to reject 
or accept either hypothesis.  
The use of Bayes Factor provides the flexibility – such as linking evidence, 
supporting the rare co-ordination – during Bayesian analysis. In particular, these 
advantages can be summarised by the following points: 
•    A large number of hypotheses is sometime needed to test a complex 
relationship. To determine the strength of the relations results from all these tests 
needed to be used to ensure a complete assessment. An investigator can take the 
cumulative of the BFs from the tests during an analysis.  
•    A large P-value can tell that the result found is not statistically significant. But 
one can simply find a large P-value just because there is less or no indication of 
that particular relation in the available data. The use of priors allows taking 
account of this uncertainty within the Bayes Factor.  
2.5   Summary 
This chapter examines the potential benefits of Bayesian methods for introducing new 
changes in health service. It reviews the existing approaches to examine the 
effectiveness of complex health care initiatives and discuss the pitfalls of these 
approaches.   
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Chapter 3 
Review of Bayesian Networks  
The chapter discusses the basic components of Bayesian Networks (BNs). The chapter 
starts with an introduction to BNs and then discuses, in Section 3.1.1, how a BN can 
model both discrete and continuous variables. Section 3.1.2 discusses the methods 
developed to perform inference in a BN. Section 3.2 provides a review of the methods 
used to construct a BN, with Section 3.3 covering the tools available for constructing 
BNs.  
3.1   Introduction to Bayesian networks 
The theory of BNs has been developed since the early 1980s, building on early work by 
Pearl [41], Jensen [73], Lauritzen and Spiegelhater [74] and others. 
A BN, also known as a causal probabilistic network or a belief network, is a graphical 
model that represents probabilistic relationships among a set of variables. They consist 
of two parts: a graphical structure and a set of parameters. The structure is to represent a 
directed acyclic graph (DAG) and the parameters are to determine the Conditional 
Probability Distributions (CPDs) for the variables. 
The structure of a BN is formed by the variables – known as nodes – and links that 
connect the variables. The variables represent the factors (or the propositions) that we 
find as relevant for the domain being modelled and the links convey information about 
dependency relations between the variables. Usually, the relations within the structure 
are expressed by using the wording of family relations: for example, to describe the 
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relation formed by the link from a variable X to another variable Y, we often prefer to 
say that X is a parent of Y or Y is a child of X.  
The purpose of the Conditional Probability Distributions (CPDs) in a BN is to quantify 
the strength of the relationships that are defined within its structure. The Conditional 
Probability Distributions can be defined as: (a) Conditional Probability Table (CPT) – 
for discrete variables and (b) Conditional Probability Distributions (CPD) –for the 
continuous variables. The BN that has both discrete and continuous variables is known 
as a ‘Hybrid Bayesian Network’ [75]. The CPD of a variable has a collection of 
parameters, the number of parameters being determined by the type of considered 
variable.  
Figure 3-1 is a BN for the diagnosis of pneumonia. This model is based on the 
discussion in [76], but represents the development of the disease in a simplified manner. 
Since all the links of the BN are chosen to show that the parent variables have strong 
influence on the child variables, this can be regarded as a Bayesian Network 
representing strong associations. For example, the link Pneumonia → Fever shows that 
Pneumonia is a cause for Fever. The BN has two parents for the variable Sputum; 
Pneumonia and Mechanical ventilation regard as two separate, but interrelated, causes 
for increased (High) production of sputum. 
  
Review of Bayesian Networks 
 
 
 
40 
 
 
 
Figure 3-1  A BN formed of four variables 
One important property of BNs is their ability to represent the Joint Probability 
Distribution (JPD) for all the variables in a compact form [77]. The traditional 
approach, i.e. the chain rule, requires a full specification of the probability distributions. 
In this traditional approach, the full JPD of a probabilistic model with ! random 
variables!!,!!,… . ,!! is as follows 
This approach is complex and has the potential to introduce a high number of 
probability entries [78]. In contrast, the framework of a BN reduces the complexity 
inherent in the full joint probability distribution by reducing the number of probabilities 
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of an inference. In particular, given the structure, the JPD for the BN is the product of 
all conditional probabilities specified in the BN: 
where !"!(!!) are the parents of variable !! in the BN. The conditional probabilities are 
therefore determined by !(2 !" !! !!) parameters instead of !(2!) that they would 
otherwise require if the JPD were computed directly using Equation 3.1. Using 
Equation 3.2, the BN saves (a) the space that requires for storing the parameters and (b) 
the time that requires for computations. 
Based on the BN in Figure 3-1 the JPD by using Equation 3.1 computes as: 
 
Considering the necessary conditional independence assumptions, the JPD by using 
Equation 3.2 computes as: 
 
This representation allows us to determine the conditional probabilities for the large 
CPT, i.e. the CPT for the variable Sputum, with 2!!! i.e. 8!parameters rather than 2! 
i.e.,16 that is required otherwise. 
Further, we can calculate the marginal probability distribution for Pneumonia from:  
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Before entering any evidence, based on the prior probabilities on variables, the 
probability that a patient is producing high sputum is 74.5%. We can calculate this 
using equation 3.6. 
 
If we get the information that the patient is not receiving mechanical ventilation than 
this situation will reduce the probability of producing high sputum to 0.55 from 
Equation 3.7.  
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This probability is lower than earlier one, since we are now sure that the patient did not 
receive any mechanical ventilation. The right side BN in Figure 3-2 demonstrates that 
the evidence we enter into Mechanical ventilation does not cause any change in 
Pneumonia since the variables are conditionally independent given Sputum. 
 
 
Figure 3-2 The probability of ‘High’ sputum for no evidence (in the left BN) and the probability 
of ‘High’ sputum for no mechanical ventilation is observed (in the right BN) 
3.1.1    Static and dynamic discretisation methods 
 A BN can include both discrete and continuous variables [75]. A discrete variable has a 
finite, usually small, set of discrete values and in contrast, a continuous variable has an 
infinite number of values: that is, the variable can take any value between any two 
points on a scale. However, BNs generally require a continuous variable to be 
discredited in order to reduce the number of distinct values by dividing its whole range 
into a finite set of disjoint intervals [79].  
BN without any evidence BN with evidence in MV 
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Discretisation methods mainly fall into two types, namely: static discretisation and 
dynamic discretisation. In a static method, the intervals do not change: that is, remain 
static, while in a dynamic method the intervals change depending on the assignment of 
probability. Traditionally, a static discretisation is performed in two steps: 1) the user 
defines the number of intervals for the range of the given continuous variable and 2) the 
set of cut-off points is then determined in order to assign the probabilities. There are a 
number of methods that can help users to make the best choice when defining the 
number of intervals [80][81]. In [81], Clemen has explained ‘the bracket median 
method’ where the values of a continuous variable are divided into ! equal- width 
intervals and the median of each of the intervals is used to label the interval. In each of 
the ! intervals the assigned probability is!1/!.  
The number of intervals used influences the accuracy of a BN [82] [83] and also for the 
level of complexity for a computation [84] – resulting in a longer time to calculate the 
conditional probabilities in the BN as the number of intervals increases. As a result, to 
limit the complexity, a user likes to define a minimum number of intervals; this leads to 
more intervals in the areas where the probability is expected to be varying fastest and 
fewer, wider intervals where the probability is expected to be more nearly constant. 
Since in a static method the user would have to understand in advance what the 
probabilities will be in each area of the range, this leads to more intervals than are 
essentially required [82]. 
In [84], Kozlov and Koller attempted to overcome the limitations of static discretisation 
methods and described a dynamic discretisation method instead. The work shows that 
an iterative algorithm that can be used to perform discretisation, varying the intervals 
depending on the evidence observed. Another dynamic discretisation method was later 
proposed by Neil and his colleagues [79], and the general outline of the method can be 
found in [83] [79]. In brief, the discretisation starts by considering the whole range of 
the variable and then recursively divides the range into two intervals until an acceptable 
level of accuracy is obtained. In each of the iterations the conditional probabilities are 
calculated and inference is performed to update the probabilities given the observed 
evidence. Although the method of  [79]  is influenced by the work of Kozlov and 
Koller, but the algorithm is simpler and yet capable of achieving higher accuracy.   
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Figure 3-3 demonstrates dynamic discretisation in a continuous node with the 
distribution Normal (mean=5, variance =1) and the distribution Normal (mean=10, 
variance=5) with green and blue colour. The node has been discretised following Neil’s 
method. The result clearly shows wider intervals in those areas where the probability is 
more constant – at the centre and extremes of the normal – and narrow intervals 
elsewhere. 
 
 
 
 
 
 
 
Figure 3-3   Dynamic discretisation in a continuous node with Normal (5, 1) and Normal (10, 5)
  
In general, a dynamic discretisation method let us to model a BN by producing more 
accurate intervals in the areas that matter the most. In addition to this, the adjustments to 
the intervals in response to new evidence also help to ensure that a greater accuracy is 
obtained in the BN. Because of these advantages dynamic methods are most suitable for 
incorporating continuous variables with those that have discrete states [85], and 
consequently, have been applied by many to deal with clinical problems where some 
factors of interests have to be measured using a continuous scale. In this thesis, the BN 
needs both discrete and continuous variables, so we have preferred to use a dynamic 
method for discretisation. 
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3.1.2    Inference in Bayesian networks 
A Bayesian Network can update the probability of any unknown variable. In particular, 
given evidence into some variables the model calculates the posterior probabilities for 
the variable of interest. However, many BNs are complex, which makes it impossible to 
perform Bayesian inference calculations manually. Due to this, an increasing number of 
researchers have turned their attention to develop efficient methods of Bayesian 
inference. Some of the classic methods for exact inference are summarised in Table 3-1. 
Table 3-1 Methods of Bayesian net inference 
Author Year Description 
Perl [86] 
 
1986 A message propagation algorithms whereby the probability 
distributions for each variable update in response to observations 
of one or more variables. Pearl’s original algorithm applies only 
to networks that are trees but similar algorithms have since been 
used for approximate inference in general BNs. 
Shachter [87] 1988 The algorithm reverses links until the explanation of the 
probabilistic query is obtained from the network 
Lauritzen and 
Spiegelhater [74] 
1988 The ‘Junction tree’ algorithm initially transforms the BN into a 
tree, clustering some variable together. Inference is then done by 
message passing, using an algorithm similar to Pearl’s. 
Zang and Poole [88] 1994 A variable elimination algorithm whereby variables eliminate 
after summation. 
 
3.2   Construction methods for Bayesian nets 
BNs provide an ideal mechanism to model problems that involved uncertainty. At the 
same time, a network can be formulated to combine all the relevant domain information 
in an intuitive way. The links can represent cause-effect relations between variables so 
that it is possible to design the relations in a BN from the understanding of domain 
experts. 
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The steps necessary to construct a BN model successfully are: 
•     Step 1: Identify the important variables to be included in the model. 
•    Step 2: Define the relationships between variables to complete the qualitative 
part of the model. 
•    Step 3: Assess the prior and conditional probabilities to create the quantitative 
part of the model. 
Identification of variables  
Usually the expert finds it easy to determine the relevant variables. An extensive 
analysis of the purpose of the network under construction also helps to find them [89]. 
In [90] Heckerman suggested the following four checks for selecting variables: 
• Correctly identify the goals of modelling (e.g. prediction versus explanation  
versus exploration); 
•  Identify many possible observations that may be relevant to the  problem; 
•  Determine what subset of those observations is worthwhile to model ,and  
•  Organise the observations into variables that contain mutually exclusive and 
collectively exhaustive states”[90]. 
The values (also known as states) of any variable (discrete or continuous) need to 
represent the level of details that is required for the proposed use of the BN. In a 
discrete variable, the values must satisfy the 1) mutually exclusive and 2) collectively 
exhaustive properties. The mutually exclusive property ensures that in the variable no 
one value overlaps with another while the collectively exhaustive property ensures that 
all the possibilities for the variable are considered within the values of the variable.  
 
Review of Bayesian Networks 
 
 
 
48 
 
Finally, a BN is usually modelled based on the following three categories of variables 
[73]: 
•    Hypothesis variables: these variables’ values are either not observable at all or 
can only be observed at an unacceptable cost. The primary task in modelling a 
BN is to identify these variables. 
•    Information variables: these variables’ values are possible to observe and have 
relations with the hypothesis variables. 
•    Mediating variables: these variables are included to meet special purposes – 
such as to simplify the conditional probabilities in the BN. 
Defining the relationships  
In addition to causal relations, one can also capture various other relation types – such 
as deterministic, statistical and analogical [91]–by drawing links between the variables 
for the qualitative part of the BN. In [91], Neil et al. suggested that the direction of a 
link should be defined carefully and recommended five types to reasoning, referred as 
idioms, to consider different problem descriptions while constructing the BN. These are: 
definitional/synthesis, cause–consequence, measurement, induction and reconciliation. 
•   Definitional/Synthesis idiom – this idiom can be used to represent relations that 
are deterministic or definitional such as!! = !×!. Here the synthetic node !!is 
determined by the values of the parents ! and!!. Thus, the use of synthetic 
nodes can ease calculation or understanding, and create hierarchies of sub-
attributes to define complex super attributes.  
•   Cause-consequence idiom – this idiom can be used to model a  causal process in 
terms of the relationships between its causes and consequences. The 
relationships are represented using arrows, where the direction of an arrow 
indicates causal direction, given by knowledge that change that occurs in the 
cause represented by the causal variable affects the phenomenon modelled by 
the consequence variable. The conditional probability table within the idiom 
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models the uncertain dependencies between causes and consequences. 
•   Measurement idiom – this idiom is used to model the limits of our ability to 
make measurements accurately. The steps involved within the idiom are (1) the 
true value that is to be estimated by the measurement is distinguished from the 
measurements, and (2) the way the measurement instruments interact with the 
measured entity is modelled. The use of such an idiom helps to explain away 
false positive results. 
•   Induction idiom – this idiom represents the process of performing inductive 
reasoning, where a set of similar entities is used to obtain an estimate about a 
future entity. 
•   Reconciliation idiom – this idiom reconciles independent sources of evidence 
about a single attribute of a single entity, where these sources of evidence have 
been produced by different methods. In addition, it combines uncertain 
definition model with causal inference model and combines information from 
various causal models. 
Assessing the probabilities  
The final step of the construction process is to assess the prior or conditional 
probabilities for each of the variables. The conditional probability, ! ! !" ! !defines 
the probably distribution over the states of each variable ! given its parents!!" ! . If 
the variables are discrete, the distributions represent as Node Probability Tables (NPTs) 
and otherwise represent as Continuous Probability Distributions (CPDs). An NPT 
express the probability of each value of the child given each combination of values of 
its parents. However, for a variable without any parent the NPT express the prior 
probability for each value of the variable which usually derives from the domain expert.  
 
 
Review of Bayesian Networks 
 
 
 
50 
 
In general, a BN’s construction does not always follow the steps in order and often the 
steps are repeated several times until an optimal network has been constructed. 
In [92], Verduijn et al. suggest that the construction process should start from the 
outcome variable and then continue by selecting the variable’s Markov blanket1 to 
ensure the best predictive feature subset for this outcome variable. The study applied the 
process recursively until a feature subset has been assessed for each variable that is to 
be included in the Prognostic Bayesian Network (PBN), by taking a top-down approach. 
In [93] Laskey and Mahoney construct a BN by makings several ‘network fragments’, 
of which each represents different problem instances of the domain. These fragments 
are then combined together to model the domain with a complete BN. According to the 
study, a network fragment should remain separate from other fragments, and should be 
formed respecting the syntax and semantics of BNs.  
However, the following three approaches are common to studies that focused on BNs’ 
constructions: 
•   constructing a BN using the knowledge of domain experts; 
•   learning both the parameters and the structure of the BN from historical data; 
•   constructing a BN using both domain knowledge and historical data; 
We discuss these approaches in more detail in Section 3.2.1, 3.2.2 and 3.2.3 below.  
 
                                                
1 The Markov blanket of a variable ! in a Bayesian network is the set !! of neighbouring variables that 
separate the variable from all other variables [92]. 
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3.2.1    Constructing BNs based on domain experts 
Many researchers have constructed BNs for applications in various domains based on 
the knowledge of experts [88][94][95][96][97][98][99]. In [98], the authors constructed 
a BN for predicting the probability of breast cancer based on a number of risk factors, 
using expert knowledge. They concluded that both experts and literature should be used 
to provide sufficient information regarding the associations between different 
radiological features and breast diseases.  
During a BN construction process, experts also make causal assumptions based on their 
knowledge of the domain that is being considered. Knowing that there exists a relation 
between two variables, the experts must then identify the direction. A set of such 
directed relations forms the complete structure of the problem domain 
Once the structure is complete, the experts then focus on quantifying the model with 
probabilities. There are a number of techniques which can assist in estimating the 
probabilities. Details of these techniques are given in [100][101]; we do not review 
them here as this thesis makes no use of probabilities elicited from experts. 
The expert dependent approach to building a BN, including both structure and 
parameters, assumes that the experts should be able to express their knowledge and 
estimates precisely and accurately. However, this is known not to be the case and in 
particular experts from the clinical domain often struggle to articulate the knowledge 
needed for constructing an expert system [102]. In [103] the authors stated that since the 
relations in their models have been specified from the domain experts these models 
have the potential of being biased. Studies have also shown that the parameters 
estimated by experts are subject to cognitive biases [86]; a demonstration of this was 
made in [104].            
3.2.2    Learning BNs from data 
The approach of learning a BN from data can be considered to fall into two categories: 
the first, simpler, category uses an algorithm to learn the parameters of a BN from a 
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dataset, when the structure of the BN is given; the second learns both structure and 
parameters. We consider these in turn.  
Learning parameters 
The most common approach is to calculate parameters based on the relative counts of 
the outcomes; however, this assumes the data are complete. When the data has some 
missing values, a common approach parameter learning is Maximum Likelihood 
Estimation (MLE) [105][106]. The method uses an Expectation-Maximisation (EM) 
algorithm to find these maximum estimates of parameters [107]. EM is an iterative 
method in which iteration alters between an expectation step (E), and between a 
maximisation (M) steps. The E-step computes the expectation of the likelihood based on 
evaluation using the initial estimate of the parameters, and the M-step computes the 
maximum likelihood estimates of the parameters by maximising the expected likelihood 
that is found on the expectation step. The estimated parameters in this M-step were then 
used to determine the distribution of the variables in the next E-step.   
Learning the structure 
Various algorithms have been developed for learning the structure of a BN, and these 
algorithms mainly fall into two categories: search-and-score based methods and 
constraint based methods. The former approach considers learning as a model selection 
problem. Algorithms of this approach search the space of all candidate structures for the 
variables by using a heuristic for the one that best represents the probabilistic 
relationships with respect to data [108].  
The latter approach considers learning as a problem that requires finding structure from 
the idea of independence. Algorithms of this approach take account of some predefined 
constraints to learn relations from data. In general, a constraint is derived by comparing 
the result of a test of conditional independence (CI) in the data to a threshold. The 
structure in which all the relations meet such constraints considers as the best for 
explaining dependencies and independencies with respect to the data. 
Various scores have been considered for learning BNs structure using the score-and-
search algorithms, such as: the likelihood score, the Bayesian information criterion 
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(BIC) score, the Akaike information criterion (AIC) score and the Bayesian score. The 
likelihood score is determined from the likelihood of data given the structure, and then 
the maximum of the function is used to calculate the maximum likelihood score of the 
BN. The Bayesian score is a measure of how well a given structure,!, fits the data, !, 
is defined as: 
 
Equation 3.8 is essentially the posterior probability of !, given the data, !. While 
learning, a score-and-search algorithm has to maximise the score and the Bayesian 
approach performs this computation using Bayes Theorem: 
 
The denominator of the equation does not help to differentiate between different 
structures, and therefore, in order to maximise the score the numerator needed to be 
maximum. If we ignore ! ! ,!then the score calculates as: 
  
To compute!! ! ! , the Bayesian approach averages over all possible parameters, 
weighing each by their posterior probability: 
Search-and-score algorithms are heuristic and often the basis of this is a greedy search 
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(GS), but other methods are also used. Daly et al. [109] give a review of the methods 
that have been developed for learning the structure of Bayesian networks from data.  
Michalowski et al. [110] construct the structure of a Bayesian Belief Network (BBN) 
based on the K2 algorithm [108], which uses a greedy search method, starting from the 
assumption that a variable has no parents. K2 works in a loop over all the variables: at 
each stage it adds incrementally the parent whose addition increases the probability of 
the resulting network. When it becomes impossible to increase the probability of the 
network given the data by adding another single parent, the process stops and gives the 
BBN that has the maximum posterior probability on the data.   
For the structure of a data-drive Bayesian network Suebnukarn et al. [111] have used 
the Necessary Path Condition (NPC) [112] – a constraint based learning algorithm. The 
motivation was to identify all the conditional independence and dependence relations 
between variables. The learning begins with a set of statistical tests and completes the 
structure through several steps. The steps are followed to establish directed links based 
on conditional independences as found from the tests while creating a directed acyclic 
graph. 
3.2.3    BNs from data and domain experts 
Researchers have also considered combining expert knowledge and data to construct a 
BN. In this method, the causal structure of a BN is derived from experts, who mostly 
acquire relevant knowledge from their experience or from the available literatures.  
Then, the parameters for this structure are learned from a dataset to complete the model 
construction. The method is now very popular in epidemiology. In particular, 
researchers prefer to construct a causal structure from the experts in advance and uses it 
to guide the analysis of epidemiological data afterwards [113][114] 
In addition to above, there are other ways to combine the knowledge of expert with data 
for constructing a BN. Khan et al. [115] incorporated knowledge with data for learning 
parameters. They outlined parameter constraints using domain knowledge and 
incorporated these constraints in a separate BN model. The study data samples were 
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incorporated in this model to learn parameters given constraints. In [9], Gevaert et al. 
have specified the priors for the structure and parameters from domain experts. Each of 
the structure priors is essentially a probability that corresponds to each directed link 
from all combinations of links between two variables. The model is based on three 
variables, this has generated six links and the experts have therefore specified six priors 
for the structure. Then, these priors were assessed by the experts and changed according 
to the study dataset. Their approach has demonstrated that the prior probabilities about 
the structure of a BN, as specified from experts, could be used to guide in learning the 
structure considering data.  
In Dekker et al.’s [7] learning approach, the domain experts have made a draft structure 
at first. Taking this as a starting point a search algorithm – the Markov Chain Monte 
Carlo (MCMC) method [116]–was later used to select the optimal structure that results 
in producing a higher predictive likelihood on data. 
3.3   Tools for BNs 
There are various software tools that are used both to construct a BN and for completing 
all the necessary inference calculations. Some tools are non-commercial 
[117][118][119][120][121][122][123][124][125][126] and others are commercial 
[127][128][129][130][131]. In [132] Murphy has listed all the features of each of the 
above software tools to help developers in deciding which one is the best in terms of the 
required BN and the extent of its support. 
In this thesis we make use of the AgenaRisk software tool [127] for constructing all the 
required BNs. This is because among all the available tools, AgenaRisk has all the 
features that we need to conduct and complete our study. In particular, the tool: 
• has a powerful graphical user interface;  
• allows modellers to construct a complex and large BN model in a simple way; 
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• provides a Java application program interface (API) allowing both model 
construction and model inference to be scripted so that, for example models 
can be generated from a data file; 
• supports hybrid BNs with continuous variables handled using dynamic 
discretisation. 
Taking account of all the above, we judged AgenaRisk to be the best tool for our study. 
However, it does not yet provide supports (a) for learning the structure of a BN from 
data and (b) to evaluate the strength of a causal relation, in a straightforward way, but it 
enables us to complete both (a) and (b) by experimenting with the underlying Java code. 
In particular, the API of the software tool allowed me to go to any extent during the 
implantation phase of the learning algorithms that I proposed for my studies.    
3.4   Summary 
In this chapter we have described the basic concepts of Bayesian networks, including 
BN inference, static and dynamic discretisation methods, together with the steps needed 
to construct a complete BN model. We presented some examples of the approaches used 
to construct BN for specific applications in a number of different categories. Finally, we 
reviewed some BN tools and explained our selection of AgenaRisk.
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Chapter 4 
Bayesian Networks in the Clinical and 
Health Care Domain 
This chapter surveys the existing applications of BNs to clinical support. Section 4.1 
looks at the ways that BNs have been used in the clinical and health care domain. 
Section 4.2 discusses the methods that have been applied to evaluate the performance of 
these networks. Section 4.3 examines the use of these techniques on a sample of 
published applications. Finally, Section 4.4 compares the existing practices against the 
research objectives of this thesis. 
4.1   The use of BNs for clinical reasoning 
BNs are popular tools for modelling risk and uncertainty. They have been successfully 
applied in diverse fields within the clinical domains. We review a number of such 
studies in this section by categorising them according to the tasks that they support. 
4.1.1    Diagnosis 
Usually a clinician performs diagnosis of the diseases of a patient from the symptoms, 
so that ‘diagnostic reasoning’ has become the general term for inferring information 
about causes (e.g. a disease) from observed consequences (e.g. symptoms of illness). 
However, diagnosis is never certain; even after taking all the symptoms into account the 
clinician remains unsure – to some extent – about the true condition of the patients. To 
avoid mis-diagnosing the patient, this uncertainty must be considered. BNs have been 
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found to be a suitable framework for representing uncertainty in clinical problems. This 
section reviews a number of studies that use BN models for diagnosis.  
Alvarez et al. [133]  used a BN for diagnosing pyloric stenosis, and concluded that this 
model is better for detecting the disease than clinicians and reduced the number of 
recommendations for ultrasounds. Kline et al. [134] investigated a BN to estimate 
patients with a low pre-test probability (between 0% to 2% ranges), for helping 
clinicians making decisions about diagnostic tests for embolisms. Also for the diagnosis 
of pulmonary embolism, Luciani et al. in [135] described the use of BayPAD – a 
probabilistic expert system –, for improving the accuracy of diagnosis. Haddawy et al. 
described a BN in [136] to diagnose and select the procedure for patients with suspected 
gallbladder disease.    
Watt and Bui [103] constructed a BN from a combination of domain expertise, data and 
the findings of a literature review. The BN was for the prediction of knee osteoarthritis 
(OA); the authors concluded that the model appeared to be effective in identifying the 
symptoms that correspond to the presence of OA in the knee of a patient, but the 
knowledge taken from the experts can introduce bias into the relations modeled in the 
BN. 
A number of BNs have also developed to estimate an individual risk of diseases 
[98][137][138][139][140][4]. In addition to the detection of a disease, BNs have also 
been developed and used to identify patients to decide guideline eligibility for disorders 
such as asthma [141], and pneumonia [142].  
4.1.2    Classification 
The aim of a classification model (also known as a classifier) is to categorise cases into 
one of the ! mutually exclusive outcomes. Most of the BNs that have been developed to 
perform diagnosis tasks can be regarded as Bayesian classification models, but 
classification is more general since most diagnostics models classify patients into one of 
two categories.  
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Liu et al. [143] applied a Bayesian classification model to differentiate between benign 
and malignant Thyroid Nodules by using sonographic features. The model includes 
features that are known to be the predictor of malignancy as well as factors that 
significantly influence in observing malignant nodule, such as age and gender. The 
variable Age had two discrete states: < 50 years and >=50 years. Because of this it was 
not possible for the classifier to make any distinction between a patient aged 25 and a 
patient who aged 49, or between a patient aged 50 and a patient aged 85. 
In [144] Chattopadhyay et al. present a naive Bayesian classifier to predict 
presence/absence of dental diseases from a set of parameters indicating toothache 
among study patients. Lee et al.[145] proposed a Bayesian classifier to identify 
malignant renal cyst. They considered the findings from experts as a risk to the 
performance of their BN classifier for predicting malignant renal cysts. 
Further, Wu et al. [146]  introduced a Bayesian classifier in an attempt to develop a 
computer aided diagnosis of Cerebral Aneurysm, Burnside et al. [147] proposed a 
model for predicting breast cancer, and Blanco et al. [148] applied a Bayesian classifier 
for predicting the survival rate within the first 6 months after Transjugular Intrahepatic 
Portosystemic Shunt (TIPS) placement. While the nature of these models is binary, 
there are also other Bayesian classification models which consider multiple, i.e. more 
than two, outcomes during a classification task.   
Stojadinovic et al. [149] developed a Bayesian classifier for predicting breast cancer 
risk in younger women (age < 40 years). The classifier is used to categorise each 
woman’s breast cancer into one of three levels: benign, malignant and pre-malignant. 
The study was based on 591 women and the dataset contained information about age, 
ethnicity, clinical history, hormonal information, breast density and size, risk estimate 
(from a Gali model), results of imaging and biopsy. However, the study demonstrated 
that the recruitment process of study subjects isn’t really a straightforward task and had 
to be managed carefully. 
Bayesian Networks in the Clinical and Health Care Domain 
 
 
60 
 
4.1.3    Prognosis 
BNs that predict the outcome of an event in the future are known as Prognostic 
Bayesian Networks (PBNs). With a focus towards the future, uncertainty is even more 
important in PBNs than in the BNs developed to support diagnoses. The structural 
representation of a PBN can model the time-variant nature of a problem to allow 
predictions to be performed in stages. At each stage, the model uses all the information 
that has become available at the time of the stage to perform the prediction.   
Verduijn et al. [150] developed a PBN for the domain of cardiac surgery using variables 
identified from three stages: pre-assessment, operation and recovery (postoperative). 
Taking account of the complications that occur during the operation and postoperative 
stay of a patient, the PBN predicts mortality. The study is based on data of 10147 
patients who had cardiac surgery in their selected hospital between January 1998 and 
November 2004. The PBN included multiple outcome variables, namely hospmort, 
ORmort and postORmort, which respectively represent the hospital mortality, operative 
mortality and postoperative mortality of a patient. By dividing the dataset into two 
subsets (a) training and (b) testing, the authors have learned the model based on (a) 
whereas used (b) to validate its performance. Further, the predictive ability of the PBN 
was compared with another network (Figure 4-1) that maintains the time-dependent 
ordering of the variables of the PBN learnt using the Minimum Description Length 
(MDL) principle.  
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Figure 4-1 MDL based PBN to demonstrate the time dependent ordering of variables 
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Other BNs developed in the clinical domain to predict outcomes include BNs for 
assessing morbidity and mortality in patients who had coronary surgery [10], liver 
transplantation [96], injury [151], suffer with sickle cell disease [152] and lung cancer 
[153], for predicting the outcome of endodontic treatment [111] and the response to 
bronchodilator medication [140]. 
In [140] a hybrid Bayesian network predicts Bronchodilator response (BDR) by taking 
account of simultaneous associations and interactions between variables. The model 
was based on data from a cohort of 308 Caucasian Childhood Asthma Management 
Program (CAMP) – a clinical trial – subjects, and constructed with a greedy search 
method. The predictive ability of the model was determined through a fivefold cross-
validation method (see Section 4.2.1). According to the authors of the study, some 
variables that may contribute significantly to BDR may have remained unidentified and 
were therefore absence from the search process, and this was the reason for obtaining a 
disappointed performance from the model. 
BNs have also been used to obtain predictive values to provide assurance of better 
allocation of resources and management of health care. For instance, in [154] the 
authors developed BNs to monitor patients and aid in drug therapy. Their system 
incorporated both general population data and incoming patient data to provide patient-
specific models. The BBN-RPP model in [110] provides probabilities over the values 
(met or delayed)  of the outcome variable LOS (length of stay) and helps to assess the 
impact of a patient’s outcomes and activities  on his length of stay at a hospital after 
surgery. The triage model in [97] estimates the probabilities of different decisions in 
order to determine if a patient coming to an emergency department (ED) actually 
requires hospitalisation. Further, [155] develops a model to predict the length of stay of 
patients as a tool to help the management of hospitals to improve better geriatric health 
care.  
This section has shown that BNs have been developed for a variety of application with 
several different styles of reasoning. But in all cases, the aim of the BN is primarily to 
update the probability distribution of one, or a small number, of outcome variables. As 
we will see in later chapters, the focus changes when we attempt to use a BN to analyse 
data gathered by observing process in operation. 
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4.2   Performance of Bayesian nets 
Researchers have mostly assessed the predictive performance of a BN by examining 
three abilities: 1) discrimination ability 2) generalisation and 3) calibration. In this 
section, we review the methods to assess each of these three abilities. The following 
section looks at the way these methods have applied to the clinical BN projects 
reviewed in Section 4.1. 
4.2.1    Discrimination or classification ability 
The discrimination ability of a BN model measured how well the model can distinguish 
between two or more classes. Either a model can be tested using a separate dataset for 
testing (as opposed to training the model) or a cross validation can be used. In general, 
an N-fold cross validation divides the study dataset into N equal subsets and from these 
N-1 datasets are used to learn BNs accordingly and the Nth dataset is used to test the 
BN. This is repeated for N separate tests, so that all data points have been used both to 
train and to test (though never together). The performance of the N tests is averaged.  
The results of a test separate cases into four categories, namely: true positive (TP), false 
positive (FP), true negative (TN) and false negative (FN). The names assume the 
outcome variable is Boolean, but the process can be used for any 2–state. Using these 
categories, the measures shown in Table 4-1 are derived for evaluating the network. 
These measures assume an ‘operating point’ for the classifier. The operating point is 
determined by the probability threshold used for classifying the outcome into the two 
categories: the obvious value of 50% is not necessarily the best; instead different 
operating points trade-off between sensitivity and specificity. 
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Table 4-1 Measures for evaluating the ability of a Bayesian network 
Performance!
measure!
Definition!
Sensitivity 
 (!")  !" = !"!"!!" 
Specificity (!") !" = !"!" + !" 
Positive Predictive 
Value 
 (!!") !!" = !"!" + !" 
Negative Predictive 
Value !(!"#) !"# = !"!" + !" 
Correlation 
Coefficient 
 (!!) !!= !"×!" − !"×!"!" + !" × !" + !"# × !" + !" ×(!" + !") 
 
To show the discriminating ability of a BN at different operating points, a Receiver 
Operating Characteristic (ROC) curve can be used. To obtain an ROC curve, one 
evaluates the performance of the model with a number of possible threshold values. The 
ROC curve then plots the sensitivity against the specificity for different threshold values 
to show the overall performance of the model. The area under the ROC (AUROC) is 
used as a measure of the model’s performance. It ranges from 0.5 to 1, where the lower 
value indicates that the model performs no better than random guessing whereas the 
upper value indicates that the model performs its task perfectly. 
Rather than creating a test dataset from that used to develop a BN model, many have 
used an independent dataset for testing. Figure 4-2 is the ROC curve generated in [1] 
when the authors test their BN – that has been developed from a cohort of 9349 patients, 
with an independent dataset containing 992 patients. 
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Figure 4-2 The ROC curve from the independent dataset in [1] 
While an AUROC reveals how accurate a model is for discriminating cases into two 
outcomes, the measures mostly used for a BN that concerns multiple (more than two) 
outcomes are its sensitivity, specificity and positive predictive values. For instance, the 
BN in [97] models the process followed by a triage nurse to handle patients arriving in 
an Emergency Department (ED), with one of four possible triage decisions: (1) call 911, 
(2) go to emergency room, (3) visit doctor in the next two business days and (4) self 
care. To assess the performance of the model, the study only measures the sensitivity 
and specificity of the model for each decision.  
Miettinen et al. [156] constructed a number of BNs from several scoring functions and 
have applied them to classify a case into one of the six otoneurological diseases. Each 
of the models was tested using data in a ten-fold cross validation and to assess this 
method for representing the dependence relations between the identified attributes of 
otoneurological data, they calculated the average of the sensitivities, positive predictive 
values and accuracies, which is then compared with the result of the tests performed 
with neural networks.  
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Instead of using any of the techniques described above Reynolds et al. [157] have 
calculated error rates to assess the predictive abilities of the BN classifier they 
developed. In particular, they have applied the BN on 46 tumours to classify each into 
one of seven classes, choosing the one with for which the BN predicts gives the highest 
probabilities; they then calculate three different errors to measure the performance of 
the classifier. 
4.2.2    Generalisation ability 
The generalisation ability of a BN model is generally measured by testing the model 
with a test dataset, separate from the training dataset. It is essential to consider 
generalisation to know how well the model will perform when it is used for cases that 
haven’t been used in its development. In addition to the use of a test dataset, there are 
also other ways in which the generalisation ability of a BN prediction model can be 
assessed. In some studies, after obtaining the results from a test, the authors have further 
compared them with the values processed by (a) another model and (b) the domain 
experts. 
In most of the cases seen, the ‘another model’ used is essentially a model that is 
currently in use for providing probabilistic estimations and the BN is learned 
completely from the study data. If there is no model currently in use, the relevant 
probabilities (for e.g. prognosis) can be estimated by the domain experts.  
4.2.3    Calibration ability 
The calibration ability describes how close the estimates of the model are to the true 
underlying probabilities [158]. A common measure is the Hosmer-Lemeshow 
(HL)!goodness-to-fit statistic [159], which summaries a calibration curve. In order to 
calculate the HL goodness-to-fit statistic, the cases are placed into groups by first 
predicting the outcome for each case from the model, and then ranking the cases 
according to the predicted probabilities. The statistic is then derives from both the 
predicted probabilities and actual results of each group. To explain how well a model fit 
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to the data, many studies use the P-value of the derived HL goodness-to-fit statistic. 
Despite this widespread practice, Biagioli et al. [10] have stated that for a large dataset 
the use of P-value can lead to misleading conclusions. 
4.3   Use of the performance measures in 
practice 
In Section 4.1 we categorised a number of studies according to the task that the BN they 
develop supports. In this section, we tabulate the measures used for evaluating the 
performance of 32 published BNs, covering diagnosis (Sections 4.1.1), classification 
(Section 4.1.2) and prognosis (Section 4.1.3). The results are in Table 4-2. 
 
Table 4-2  Evaluation methods and measures for BNs discussed in sections 4.1.1 to 4.1.3 
Authors Evaluation method Performance measure 
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Alvarez et 
al. [133] 
No Yes No No No Yes Yes Yes No No Yes No 
Kline et al. 
[134] 
No No No No No Yes No No No No No A test 
threshold 
computed 
from 
Pauker and 
Kassirer 
[160]’s 
formula 
Luciani et 
al. 
[135] 
No No Yes No No No Yes Yes No No No No 
Haddawy et 
al.[136] 
No Yes No No No No No No No No No No 
Burnside et 
al. [98] 
No Yes No No No Yes Yes Yes Yes No No No 
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Cruz-
Ramírez et 
al. [137]  
No No No Yes No No Yes Yes Yes Yes No No 
Maskery et 
al.[161] 
No Yes No No No No No No No No No Brest 
pathology 
literature 
for 
evaluation 
Watt et 
al.[103]  
Yes No Yes No No Yes Yes Yes No No No No 
Sanders and 
Aronsky 
 [139]  
No No No Yes No Yes Yes Yes Yes Yes No Positive 
likelihood 
ratio and 
negative 
likelihood 
ratio 
Himes et al. 
[140] 
Yes No No No Yes Yes Yes Yes No No No Standard 
error for 
the 
AUROC 
Charitos et 
al.[4] 
No No Yes Yes No Yes Yes Yes No No No No 
Sanders and 
Aronsky 
[141] 
Yes No No No Yes Yes Yes Yes Yes Yes No No 
Kline et 
al.[134] 
No Yes No Yes No No No No No No No 95% 
Confidenc-
e Interval 
Aronsky et 
al. 
[142] 
No No No Yes No Yes Yes Yes Yes Yes No Positive 
likelihood 
ratios, 
negative 
likelihood 
ratios and 
 test 
effectivene
-ss 
Stojadinovic 
et al. [149] 
Yes No  No No No Yes No No No No No No 
Lee et al. 
[145] 
Yes Yes No No No Yes Yes Yes No No No No 
Liu et al. 
[143] 
No Yes No Yes No Yes Yes Yes No No No No 
Chattopad-
hyay et 
al.[144] 
No No Yes Yes No Yes No No No No No No 
Wu et 
al[146] 
Yes No Yes No No No No No No No No Analysis of 
the error 
rate and 
the image 
recognition 
rate 
Burnside et 
al.[147] 
No No Yes No No Yes No No No No No No 
Blanco et 
al.[148] 
Yes No Yes No No Yes No No No No No Calculated 
the Brier 
score to 
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estimate 
the 
classifier 
calibration 
Verduijn et 
al. [150] 
No No Yes No Yes Yes Yes Yes No No No No 
Biagioli et 
al. 
[10] 
No No Yes Yes No Yes Yes Yes No No Yes No 
Burd et al. 
[151] 
Yes No Yes Yes No Yes Yes Yes No No Yes No 
Sebastiani et 
al.[152] 
No Yes No No Yes Yes Yes No No No No Error rate 
Jayasurya et 
al.[153] 
No No Yes No Yes Yes Yes Yes No No No No 
Suebnukarn 
et al. [111] 
Yes Yes No No No Yes Yes Yes No No No No 
Himes et 
al[140] 
Yes No No No No Yes Yes Yes No No No No 
Berzuini et 
al. [154] 
No Yes No No No No No No No No No No 
Michalows-
ki et 
al.[110] 
No No Yes Yes No Yes Yes Yes No No No No 
Sadeghi et 
al. 
[97] 
Yes Yes No No No No Yes Yes No No No Chi-square 
test 
Marshell et 
al.[155] 
No No Yes Yes No No No No No No No Chi-square 
test 
4.3.1    Critiques of the performance methods 
Table 4-2 presents various existing methods to evaluate the performance of a BN 
model. The table shows that in many cases the accuracy of a model constructed from a 
training dataset has been assessed on a test dataset. While some studies used an 
independent dataset to test a BN model, others have mainly selected the test dataset 
from the data used during the development, perhaps using a cross validation. 
Ohno-Machado and his colleague [162] show concern about separating a dataset into a 
test dataset and a training dataset. Indeed, there are various studies within the clinical 
literature in which the authors conclude that a significant difference between the sizes or 
qualities of a training dataset compared with the test dataset is the foremost reason for 
the BN constructed in the study not being applied in practice [152][163][9][164]. In 
[161] Maskery et al. discussed that using train-test datasets to validate a BN’s ability is 
only suitable when there is only one outcome for the problem of interest. It follows that 
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the methods of cross-validation are not appropriate for validation if a BN provides an 
adequate representation of observed data. 
Further, the table shows that the studies have mostly calculated the area under an ROC 
curve to assess a BN’s accuracy in making predictions. The ROC curve for a BN results 
from the sensitivity and specificity of the model. In [165] Yet et al. argue that the 
common measures used for the accuracy of a BN (which they refer as a scoring system 
in the study) are inappropriate for making the model acceptable in the clinical domain. 
4.4   Summary 
This chapter discussed the existing applications of BNs to medical support. First it 
investigated the ways that BNs have been used in the clinical and health care domain. 
Then it discussed the methods that have been applied to evaluate the performance of 
these networks. Following that, it examined the use of these techniques on a sample of 
published applications. 
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Chapter 5 
Case study: Evaluating Treatment 
Selections for Patients with Cancer – 
Initial BN’s Construction 
In [166] Victor Ogunsanya, a researcher from the Risk and Information Management 
(RIM) research group at Queen Mary, University of London, used a case study to 
investigate a parameter learning approach using data. His study required a small BN to 
be constructed, representing relations between three variables from the domain. A 
model of this size is insufficient of the domain. This chapter uses the same case study 
but extends the analysis- a new dataset is collected and analysed to identify more 
variables of the domain. Relations between these variables are determined using the 
knowledge of the expert Professor Hemant Kocher.  These new variables and their 
relations help to enlarge the size of the BN proposed in [166]. 
The expert who the research group consulted to retrieve information regarding the 
structure of the expert BN is Professor Hemant Kocher. He joined in Barts Cancer 
Institute in 2005 as a Senior Clinical Lecturer. Some of his academic achievements are a 
National Clinician Scientist Fellowship by the National Institute of Health Research 
(UK), an MD from Kings College London in 2003 and specialist clinical training in 
hepato-biliary-pancreatic surgery in 2005. His research interests include: liver cancer, 
pancreatic cancer, surgery of the gall bladder and bile duct, the liver and the pancreas, 
developing new treatments, risk assessment and quality improvements. The case study 
discussed in this thesis was a collaborative project and uses the data collected from 
Professor Hemant Kocher’s research group at the Barts and the London HPB 
(HepatoPancreaticoBiliary) Centre at the Royal London Hospital of Barts NHS Trust. 
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A number of consultation sessions were held to and information regarding the 
followings was extracted from judgements made by the expert: 
•  How many of the identified study variables adequately represent the MDT 
process? 
•  Which variables relate with each other? 
•  What information are there to describe a possible relationship between two 
variables? 
The HPB Centre at the Barts and the London NHS Trust (BLT) is a specialist centre 
offering treatment and care to patients with biliary, pancreatic and liver diseases with 
the help of teams of specialists consisting of oncologists, surgeons, physicians, 
pathologists, radiologists and palliative care specialists, who form a Multi-Disciplinary 
Team (MDT). The data come from the operation of the MDT meetings, at which 
treatment decisions are made; these processes are introduced in Section 5.1. The 
following two sections give an overview of the data and how the data were used to 
select variables in a BN model of the MDT outcome. This model is then used in both 
Chapters 6 and 7 as a case study for novel techniques for the evaluation and analysis of 
observed data, which are the main contribution of thesis. 
5.1   Multidisciplinary team meetings 
A multidisciplinary team meeting (MDT) is an important decision-making forum in 
medicine, especially in oncology. The objective of the HPB’s MDT is to generate 
comprehensive and coordinated care plans for patients with cancer or suspected cancer. 
Previous studies of the use of MDT meetings in oncology have shown that patients 
managed by such meetings have better survival outcomes [167], shorter waiting times 
[168], and benefits from a more robust treatment selection process [169], compared to 
those managed without formal multidisciplinary discussions. 
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Suspecting cancer as the possible disease, GPs in the BLT’s district initially refer their 
patients to one of the twelve general hospitals in the district. These patients are then 
referred to the BLT HPB centre where their cases are scheduled for further discussion in 
the MDT meetings held at the HPB centre. The meetings review imaging and the results 
of other tests, reaches a diagnosis and recommends one or more treatment options. 
 
 
Figure 5-1  The process of recommending treatments to patients referred to the MDT 
If the available information for a particular patient is insufficient for the MDT to make a 
treatment recommendation at the first meeting, the case is discussed in another meeting. 
A patient’s case can also be discussed in multiple MDT meetings if it is thought to be 
really complex. As well as choosing a treatment route, other outcomes are also possible. 
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For example, when the MDT reaches the conclusion that the probably diagnosis for a 
patient is a non-cancerous disease, the patient is discharged to other specialists. Figure 
5-1 represents the process of recommending treatments to patients referred to the MDT, 
using a flow chart. 
5.2   Data 
The source data used in this study contains records of patients who suffered with cancer 
or suspected to have cancer and were discussed at the MDT meetings held at the HPB 
centre between 2005 and 2009. During this period, meetings were usually held each 
week and the staff initially wrote up details of the patients discussed in a word 
document. Data were then extracted from these word documents and stored in an excel 
data file. In total, the file contains records of 2074 patients. Because of the way the data 
were captured, the relationship between data fields and variables in the BN is not 
straight forward. We first describe the raw data and then the way this is used to create a 
BN. 
The data file included details of seven attributes: data of birth, data of discussion (this is 
when a case is first discussed after being considered for an MDT meeting), the number 
of meetings held, affected organ, type (i.e. the severity stage of a diagnosed cancer), 
diagnosis, and treatment option. Although the data file mostly includes only one value 
for each attribute, in some cases it contains multiple values of treatments to suggest that 
the patients were recommended multiple treatments at the MDT meetings.       
A diagnosis of a patient’s cancer is made using 44 possible values as presented in Table 
5-1. Each of these values corresponds to one of the possible categories of cancer that a 
patient may have depending on the organ that had cancer. There are fifteen possible 
categories if the cancerous organ is the pancreas and five possible categories of cancer if 
the organ is the gallbladder. The numbers of possible categories of cancer when the 
organs are the liver and the bile duct of the patient are 14 and 10, respectively. 
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Table 5-1 Possible categories of cancer for each organ  
 
 
 
Organ Diagnosis 
Pancreas PDCA (Pancreatic ductal adenocarcinoma) 
PNET (Pancreatic neuroendocrine tumour) 
IPMN (Intraductal papillary neoplasia) 
MCN (Mucinous Cystic Neoplasms) 
SCN 
CP 
AP 
Cyst 
Stone 
Other 
Pseud (Pseudopapillary tumour) 
Mets (Metastases) 
Pancreas divisum 
SPN  (Solid pseudopapillary neoplasm) 
Unknown 
Liver HCC (Hepatocellular carcinoma) 
CRC Mets (Colorectal cancer liver Metastasis) 
OO Metastasis 
Fatty Liver 
Cirrhosis 
Adenoma 
FNH  (Focal nodular hyperplasia ) 
Cyst 
Hydatid Cyst 
Haemangioma 
Liver abscess 
Hepatobiliary cystadenoma 
Angiomyolipoma 
Other 
Gallbladder Cholecystitis 
Stone 
Malignancy 
Adenoma 
Other/Unknown 
Bile duct Cholangiocarcinoma 
Bile duct stricture 
Iatrogenic stricture 
Iatrogenic Leak 
PSC (primary sclerosing cholangitis) 
CBD Stone (Common bile duct stone) 
MS (Mirizzi's Syndrome) 
Inflammatory strictures 
Cholangitis 
Other/Unknown 
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The MDT meetings recommend six treatments to the patients discussed. These 
treatments are: chemotherapy, radiotherapy, surgery, palliative care, intervention 
radiology and watchful waiting. In some situations, rather than recommending a single 
treatment the meetings may recommend more than one treatments. However, it is not 
always the case that a treatment has been recommended to a patient. In these cases, the 
data file contains an entry of either (a) lost, (b) death, (c) discharged or (d) no cancer to 
indicate one of the following: 
•    The MDT was unable to trace the patient to recommend a treatment. 
•    The patient died before receiving a treatment from the MDT. 
•    The patient has been discharged. 
•    The type of the diagnosed cancer was benign. 
In addition to the main data file, additional summary statistics about the MDT were 
made available for this study. Table 5-2 presents the summary statistics covering (a) 
total number of cases discussed in each year (b) average time taken per MDT meeting 
and (c) average time taken per case for the year considered. This reveals that the 
average time taken for each patient steadily decreased over the study period. 
 
Table 5-2 Summary statistics of the MDT meetings for the study period 
 
 
 
 
Year Discussed 
patients 
(total) 
Average time 
per MDT meeting 
(in minutes) 
Average time 
per patient 
(in minutes) 
2005 7 90 12.52 
2006 10 110 11.00 
2007 15 120 8.00 
2008 20 120 6.00 
2009 30 105 3.30 
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5.3   Selection of variables 
This initial excel data file appeared to have inconsistent records for some patients which 
has caused a significant problem during the selection of variables. So some refinements 
are made to the data file based on evidence of inconsistencies. In particular,  
•    The records of the 81 patients who had no information of date of births in the 
data file have been deleted. Then, the records of 6 more patients were deleted 
because of an obviously wrong date of birth value. At this stage, the data file 
contains records of 1987 patients in total. We refer to this dataset as the 
‘Meeting data’. 
•    The records of 89 patients were deleted for having no information about the 
cancerous organs. Similarly, the records of a further 347 patients were deleted. 
This is because, for 187 of these patients the record of cancerous organs was 
unknown and for 160 patients, the cancerous organ is not any of the four organs 
(the pancreas, liver, gallbladder and bile duct) considered at the MDT meetings. 
After deleting these patients, the data file has records of 1551 patients in total; 
we refer to this dataset as the ‘Organ data’. 
•    A further 25 patients had no information on the disease type and these records 
were also deleted. This brings the total number of patients to 1526. The data file 
of the records of 1526 patients is referred to as the ‘Organ-Type data’. 
•    A further 50 patients had no or a wrong diagnosis value. The records of these 
patients were deleted and the data file now of 1476 patients is referred to as the 
‘Diagnosis data’. 
•    Finally, 30 more patients with a wrong treatment option have been identified 
and deleted from the data file. After this last refinement, a data file with 1446 
patients is obtained. This file is referred to as the ‘Treatment data’. 
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These deletions from the initial data file have enabled us to find the maximum number 
of study patients with complete records of each model variable. We selected seven 
discrete variables: Age, Year, Number of meetings, Organ, Type, Diagnosis and 
Treatment. These variables are described in detail below, noting how the original range 
of values has been mapped into the BN model. 
Age 
The variable represents the approximate age of a cancer patient at the time of the first 
MDT discussion: this is derived from his date of birth and his case discussion date. This 
age is discretised to one of the seven groups: Under 46, 46 – 54, >54 – 60, >60 – 66, 
>66 – 71, >71 – 77, and 77+. Each age group holds an equal number of patients and 
this was around 13% of the study patients.  
Year 
The variable represents the year when a case is first discussed after being considered for 
a MDT meeting and is selected from the date of discussion. The variable contains five 
values: 2005, 2006, 2007, 2008 and 2009. 
Number of meetings 
The variable represents the number of MDT meetings held per case within the period. 
For most of the cases, the recommendations of treatment resulted from just a single 
meeting. However, for some cases a recommendation required multiple meetings and 
the maximum of them was 11. The values defined for this variable are: 1, 2, 3, 4 or 
more. 
Organ 
The variable represents the cancerous organs and has four corresponding values: 
Pancreas, Liver, Gallbladder and Bile duct. 
Type 
The variable represents different cancer stages. It has three values: Benign, Malignant 
and Unknown. Note that here the value Malignant represents both malignant and the 
borderline cancers. 
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Diagnosis 
The variable represents various cancer diagnoses. Based on the cancerous organs and 
their possible types, the full set of 44 possible diagnosis categories were grouped into 
the following eight non-overlapping values: 
•  BP  = a benign cancer in the pancreas, 
•  BL = a benign cancer in the liver, 
•  BGB = a benign cancer that develops either in the gallbladder or in the bile duct, 
•  MP = a malignant cancer in the pancreas, 
•  ML = a malignant cancer in the liver, 
•  MGB = a malignant cancer that develops either in the gallbladder or in the bile 
duct, 
• Unknown = an unknown type of cancer, 
• Multiple = multiple types of cancers. 
Treatment 
This variable represents the treatments that MDT meetings recommend to the study 
patients. For some patients during a meeting experts have recommended more than one 
treatment options and thus, to ensure the mutual exclusive property for the variable a 
value, Combination, is added. A treatment that was always recommended jointly with 
other treatments was radiotherapy. Those that were recommended as a single treatment 
option correspond to the following five values: Chemotherapy, Palliative, Surgery, 
Intervention radiology and Watchful waiting. Finally, we define another value, namely 
None, to represent cases in which no treatment recommendation was made, and this 
ensures the mutually exhaustive property for the variable. 
Case Study: Evaluating Treatment Selections for Patients with Cancer – Initial BN’s 
Construction 
 
80 
 
Tables 5-3 to 5-6 present the distribution of the values of all study variables. For each 
variable the number of patients is calculated based on the stage of its selection. 
 
Table 5-3   The distribution of values of the Age, Year and Number of meetings for patients in the 
‘Meeting data’ 
Variable States Percent of patients 
(n) 
Age Under 46  
 
13%  in each group 
(260) 
46 – 54 
>54 – 60 
>60 – 66 
>66 – 71 
>71 – 77 
77+  
Year 2005 23%     (458) 
2006 11%     (222) 
2007 26%     (520 ) 
2008 32%     (631) 
2009 7%       (156) 
Number of 
meetings  
1 = Single 72.5% (1441) 
2 = Twice 25%      (492) 
3 = Thrice 2%        (45) 
4 = Four or more times 0.5         (9) 
 
Table 5-4  The distribution of the values of the Organ and Type for patients in the ‘Organ-Type 
data’ 
Variable Values Percent of patients 
(n) 
Organ Pancreas 38%     (576) 
Liver 43%     (658) 
Bile duct 14%     (210 ) 
Gallbladder 5%        (82) 
Type Benign 37%     (567) 
Malignant 60%     (916) 
Unknown 3%         (43) 
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Table 5-5 The distribution of values of the Diagnosis for patients in the ‘Diagnosis data’ 
Variable States Percent of patients (n) 
Diagnosis BP = a benign cancer in the pancreas. 10%    (153) 
BL= a benign cancer in the liver.   8%    (113) 
BGB = a benign cancer that develops either in the gallbladder or 
in the bile duct. 
  6%      (90) 
MP = a malignant cancer in the pancreas.  21%   (314) 
ML = a malignant cancer in the liver. 29%    (424) 
MGB = a malignant cancer that develops either in the gallbladder 
or in the bile duct. 
10%    (154) 
Unknown = an unknown type of cancer.   13%     (191) 
Multiple = multiple types of cancers     3%     (37) 
 
 
Table 5-6 The distribution of values of the Treatment for patients in the ‘Treatment data’ 
Variable! Values' Percent' of' patients'(n)'
Treatment Chemotherapy  6%    (91) 
Combination 13% (192) 
None  27% (384) 
Palliative 23% (262) 
Surgery 18% (262) 
Intervention radiology. 3%    (45) 
Watchful waiting 10% (144) 
 
Not all the variables in the BN model come directly from the MDT dataset. Further 
investigation identified more variables from available additional information. The 
investigation produced two variables Time per patient, which represents the average 
discussion time per case, and Total discussion time, which represents the total time 
spent per MDT meeting. The variable Time per patient is determined from the summery 
statistics stated in Table 5-2 and the variable Total discussion time is estimated from the 
values from Time per patient and Number of meetings. 
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5.4   The structure 
The model structure is determined by identifying four relation types between the 
variables, namely 1) illegal, 2) definitional, 3) impossible and 4) hypothetical. We 
discussed with a clinician who has sufficient experience about the way treatments were 
recommended through MDT meetings to identify links corresponding to each of the 
four relation types. The links are presented in Table 5-7.   
 
Table 5-7  Relation types that exist between the model variables  
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Age - * * √ √ * √    * * 
Year √ - √ √ √ * √ → * 
Number of meetings * * - * * * √ * → 
Organ * * * - * → * * * 
Type * * * * - → * * * 
Diagnosis * * √ * * - √ * * 
Treatment * * * * * * - * * 
Time per patient * * * * * * * - → 
Total discussion time * * * * * * * * - 
Symbols used for representing the relation types: 
* -   Illegal  
→ - Definitional 
- - Impossible 
√ - Hypothetical 
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Illegal relations 
The ‘illegal relation’ classification was chosen when introducing the link into the model 
would not have any reasonable interpretation. According to the expert, a link from Age 
to Year is an illegal relation as the year in which the patient was discussed depends only 
on the year when the GP referred the patient to the hospital. Similarly, a relation 
between Age and any of the four variables: Number of meetings, Diagnosis, Time per 
patient, and Total discussion time is also thought to have no reasonable interpretation, 
and hence, such a relation is decided as an illegal relation for this study. 
Definitional relations 
Although our interest is to a model based experts’ judged causal relations, the variables 
that are determined by the values of other model variables produce some definitional 
relations. There are three sets of definitional relations: a) those that exist between the 
variables Diagnosis, Organ and Type, b) those that exist between Year and Time per 
patient and c) the relation that exists between Number of meetings, Time per patient, 
and Total discussion time. In particular, 
•   A diagnosed cancerous organ and its type, i.e. severity stage, jointly indicate the 
diagnosis for the patients. For example, if the cancerous organ is pancreas and 
its cancer type is benign then the diagnosis that is determined for the patient is 
BP (benign pancreas). All known diagnoses are determined using this approach, 
but when the type of cancer remains unknown we determine the probability of 
an unknown diagnosis. Due to these features the relations mentioned in (a) are 
taken as definitional. The Bayesian network fragment constructed from these 
relations is shown in Figure 5-2. 
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Figure 5-2 Bayesian network model fragment constructed with links based on (a)  
•    The average time per case per meeting in a year provides indication of Time per 
patient. The Bayesian network fragment constructed from this relation is shown 
in Figure 5- 3. 
 
Figure 5-3 Bayesian network model fragment constructed with a link based on (b) 
•    The number of meetings held for a case discussion and the time that the MDT 
takes per case per meeting jointly indicates the total time spent in each MDT 
meeting. For the variables: Number of meetings and Time per patient, we 
therefore, define the value of Total discussion time using the formula stated in 
Equation 5.1 and take the relation mentioned in b) as definitional.  
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•    The Bayesian network fragment constructed from the links is shown in Figure 
5-4. 
 
Figure 5-4 Bayesian network model fragment constructed with a link based on (c) 
 
Impossible relations 
A variable cannot have a relation to itself; such a relation has therefore been classified 
as impossible. 
Hypothetical relations 
Each hypothetical relation is one that the domain expert thinks corresponds to a causal 
explanation. Since the definitional relations are now known, we can explain the 
hypothetical relations taking account of the following four variables: 
•    Age: the age of a patient helps to determine about the cancerous organ, type of 
the disease and recommended treatment. The hypotheses presented in Table 5-8 
reflect the above assumption of the expert. Here the variables relating to each 
hypothesis are presented as variable 1 and variable 2.  
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Table 5-8 Hypotheses for the relations between other variables and Age 
Hypothesis Variable 1 Variable 2 Description 
1 Organ Age Changes have occurred in cancerous organs 
according to the age of cancer patients. 
2 Type Age Changes have occurred in cancer types 
according to the age of cancer patients. 
3 Treatment Age Changes have occurred in recommended 
treatments according to the age of cancer 
patients.  
 
•   Year: the year of the case discussion may influence the cancerous organ, type of 
the disease, treatments recommended to the patient, and the number of meetings 
held for the case.  
Although a hypothetical relation should corresponds to a causal relations that 
exists between two variables, according to our expert a relation that concerns the 
case discussion year is confusing. In this study, the variable Year represents a 
confounding factor, for example, a factor that represents improvements in the 
technologies used for detecting cancers over the period. The confusion arises 
because this factor is not known and therefore has not been recorded in the data. 
Similar possible relations may also influence the cancerous organ, type of the 
disease, recommended treatment and the number of meetings held to discuss the 
case. The hypotheses for explaining such hypothetical relations between Year 
and other variables are presented in Table 5-9. 
Table 5-9 Hypotheses for the relations between other variables and Year 
Hypothesis Variable 1 Variable 2 Description 
1 Organ Year Changes have occurred in cancerous organs over 
the years. 
2 Type Year Cancers with a benign diagnosis have increased 
over the years. 
3 Treatment Year Changes have occurred in recommended 
treatments over the years. 
4 Number of 
meetings 
Year Multiple meetings for discussing a case have 
reduced over the years. Or, the MDT meetings 
have become more efficient over the years. 
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•   Diagnosis: the diagnosed cancer influence the treatments recommended to the 
patient and the number of meetings held for the case. 
•   The hypotheses for explaining the above hypothetical relations between 
diagnosis and other variables are presented in Table 5-10. 
Table 5-10 Hypotheses for the relations between other variables and Diagnosis 
Hypothesis Variable 1 Variable 2 Description 
1 Treatment Diagnosis A high level treatment, such as surgery, was 
recommended in situation when the diagnosis 
of cancer was complex. 
2 Number of 
meetings 
Diagnosis Multiple meetings were held in situation when 
the diagnosis of cancer was complex. 
 
•   Number of meetings: the number of meetings held may influence the treatments 
recommended to the patient, and this is explained by the hypothesis presented in 
Table 5-11. 
Table 5-11 Hypothesis for the relations between Treatment and Number of meetings 
Hypothesis Variable 1 Variable 2 Description 
1 Treatment Number of 
meetings 
A recommendation of treatments for a 
patient depends on the number of meetings 
that corresponds for the case. 
 
The structure of the Bayesian network model, we call ‘MDT BN’, that is determined 
after deciding on the four relation types between variables is shown in Figure 5-5. The 
links corresponding to the definitional relations are thicker than the links corresponding 
to the hypothetical relations.  
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Figure 5-5 Structure of the complete MDT BN model structure from the links of possible relation 
types 
5.5   Summary 
In this chapter the structure of a Bayesian network model has been constructed by 
identifying relations between variables with the help of an expert. The variables 
represent the key factors in an MDT process which has managed the patients with 
cancer or suspected cancer treated in the HPB (HepatoPancreaticoBiliary) Centre at the 
Barts and the London NHS Trust (BLT) between 2005 and 2009. The expert is a 
clinician who has sufficient experience about the way patients were managed in the 
MDT meetings held during these years. Since we have only considered knowledge of 
the expert for constructing the structure, each of the hypothetical links of the model 
remains uncertain. In the next chapter, we will refine the structure by measuring the 
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strength of each of the hypothetical relations by taking account of the data collected for 
the study.  
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Chapter 6 
Establishing the Plausibility of 
Hypothetical Relations from Data 
This chapter focuses on assessing the hypothetical links of an expert-constructed BN 
model, using data. The MDT BN, introduced in the previous chapter, is used as a case 
study to present the technique. Each hypothetical link of the model represents a causal 
relation and is assumed by an expert. However, as many researchers have shown, the 
use of knowledge often introduces bias. We therefore reassess the existence of these 
relations using the available data. 
The learning method of this study tackles the limitations seen in many existing ones. 
The method does not rely solely on data nor on expert knowledge, but uses the data to 
assess the knowledge. Overall, the method follows a Bayesian argument: the set of 
hypothetical links of the MDT BN determines a set of hypothetical models, including 
all, some or none of the links. Which of these models explains the data best? To answer 
this, we build an additional Bayesian network and learn the parameters of the different 
models, and use these values to calculate the likelihood of the corresponding model. 
6.1   Assessing the existence of a relation 
Maskery et al. [161] tried to determine if each relation of their BN model, which has 
initially established using a minimum description length (MDL) scoring algorithm, is 
important, given the data. The study weighted this importance by (a) deriving a number 
of BNs from reduced datasets and comparing these BNs with the original BN, and (b) 
assessing removal cost for links. A link removal cost is defined (i.e. an arc according to 
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the study) as the change in the MDL score between the original model and the BN in 
which that particular link has been removed. 
In [170] Friedmen et al. applied the Bootstrap method of  Efron [171] to different partial 
structures of a BN, which has been learned from data, for defining confidence about the 
existence of relations in the BN. The empirical probability of a link, which is defined as 
the fraction of occurrences in the networks learned from bootstrapped samples, is 
considered as the strengths of the link. The probability also interprets as the degree of 
confidence that the link is present in the final network structure that describes the real 
dependence structure of the original data. A similar technique for assessing relations 
between variables has also been considered by Heckerman et al. in [172]. 
In contrast to our work, these earlier studies all assume that a full BN structure is learnt 
before assessing each single relation, and the methods therefore require multiple 
structures to be developed for all the variables of the corresponding domain, to found 
one that is optimal. Further, the work in [170] is yet another example of misuse of null 
hypothesis testing. For assessing the plausibility of an expert-based association for the 
available data  we use the method introduced in [54], which considers relations between 
an effect and its causes specified in an expert model as a hypothesis and use data to test 
this hypothesis against competing hypotheses. The results from the tests reveal the 
causal relations that are supported by the data. 
6.2   The method 
The method first identifies different hypotheses in relation to the fragment that has been 
considered. Each of these hypotheses explains one possible combination of relations for 
the particular variables. 
The aim here is to assign a score to each hypothesis to indicate how well the available 
data supports that combination. 
For simplicity, each hypothesis can be considered as a model, ! ! and a test is 
performed to assign a score based on the available data! . If we denote the model 
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parameter set by a vector !! = (!!!,… . ,!!") of size! , then we can estimate (learn) the 
probability,! !! !  using Bayes’ Theorem: 
 
Now if we consider the data,! , as a vector of observations, i.e. ! = (!!,…… ,!!)  of 
size !, then for the observations Equation 6.1 changes as: 
 
Suppose that the prior probability for a parameter is always taken as 1, i.e. ! !! = 1. 
Then in order to determine how well the parameter set of model ! ! explains a number 
of observations!(!1,…… , !!), we only compute the likelihood of the model ! ! as
 
This is what we consider as the score (also known as Bayesian score) for the hypothesis, 
and the hypothesis which is best with respect to the data ! is the one which is assigned 
with the highest score.  
6.2.1    Method advantages 
In summary, this method has a number of important advantages: 
•    It allows the use of expert knowledge to be maximised. Instead of incorporating 
knowledge partially (e.g. as to determine constrains or to define structural priors 
over certain relations) a sensible model structure can be specified in order to 
address all the problems that need reasoning about. The expert will have the 
flexibility on making assumptions, and this is because there are data available to 
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check these assumptions.  
•    Complete data do not have to be processed since the interest here is not learning 
a structure from all the variables. Only one variable is selected at one time which 
enables us to prepare less data each time. 
•   The results from the hypothesis tests can be used to reveal which out of all 
expert judged relations receive support from data. .  
The method is used to check the hypothetical links corresponding to different fragments 
of the MDT BN model, in which a fragment represents expert’s assumed causal 
relations between an effect and its causes 
6.3   Hypothetical links and structure 
hypotheses 
The hypothetical links and corresponding variables can form four sub-
models/fragments. Each of these fragments only considers one child and the parents 
from the MDT BN model. Three of these fragments form from three variables and one 
from five variables. The four child variables in these fragments are: 1) Number of 
meetings, 2) Organ, 3) Type, and 4) Treatment.   
In this section first we consider each of earlier fragments and revel which of those two 
relations between the three variables is plausible for the data, and then move into the 
later fragment. 
Hypotheses of three variable fragments 
The number of relation combinations possible between a child and two parents is four. 
We set four hypotheses, each describing one of four relation combinations, to reveal 
which combination receives support from the available data.   
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Figure 6-2 depicts the hypotheses regarding the BN fragment shown in Figure 6-1 (for 
the Number of meetings variable). Table 6-1 provides the hypotheses of the variables for 
the remaining two fragments that consist from three variables. 
 
 
Figure 6-1 BN fragment for learning plausible relation between the Number of meetings and 
other variables 
Table 6-1 Hypotheses of the variables for the fragments relating to Organ and Type 
Dependent Hypothesis Description 
Organ !! Organ is independent of Age and Year. 
 !! Organ is dependent on both Age and Year. 
 !! Organ is dependent on Age. 
 !! Organ is dependent on Year. 
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Type !! Type is independent Age and Year. 
 !! Type is dependent on Age and Year. 
 !! Type is dependent on Age. 
 !! Type is dependent on Year. 
 
 
 
 
Hypotheses of five variable fragments 
The number of relation combinations possible for a fragment containing five variables: 
one child and four parents is sixteen. We set sixteen hypotheses for the Treatment 
variable, each describing one of sixteen relation combinations, to reveal which 
combination receives support of existence from the available data:  
 Figure 6-2 Hypotheses regarding the BN fragment shown in Figure 6-1 
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•   the variable Treatment is independent of all four parents . Year, Number of 
meetings, Diagnosis and Age. 1 hypothesis. 
•   the variable Treatment  is dependent on all four parents. 1 hypothesis. 
•   the variable Treatment is dependent on three out of four parents. 4 hypotheses. 
•   the variable Treatment is dependent on two out of the four parents. 6 hypotheses. 
•   the variable Treatment is dependent on only one parent. 4 hypotheses. 
The BN models for the structures stated in the hypotheses (i) and (ii) along with an 
example BN model for each of the three structures stated from (iii) to (v) are shown in 
Figure 6-3. The rest of the hypotheses are described in Table 6-2. 
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Figure 6-3 Five  BN models for representing five different hypotheses:!!, !!, !!, !! and !!" 
regarding the Treatment fragment 
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Table 6-2 Hypotheses that do not appear in Figure 6-3 
 
 
 
 
 
 
6.4   Parameters and explanation of data 
First the parameters of a possible structure – corresponding to a hypothesis – are learned 
using data in order to determine how well the structure explains the data. Each 
parameter is the conditional probability for each outcome of the child for each 
combination of values of its parents. Figure 6-4 shows the structure of an example of 
the additional Bayesian networks constructed to learn a conditional probability 
parameter. One of these additional networks is needed for each parameter of the model; 
together the additional networks are used for determining how well the parameters have 
explained the data. 
Hypothesis: Treatment is dependent on !!  Year, Age and Number of meetings !!  Age , Number of meetings and Diagnosis !! Year, Age and Diagnosis !! Year and Diagnosis !! Age and Number of meetings !!" Year and Age !!! Age  and Diagnosis !!" Number of meetings and Diagnosis !!" Age !!" Number of meetings !!" Diagnosis 
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Figure 6-4 A Bayesian network model for parameter estimation 
The purpose of each of the nodes in this Bayesian network is explained as follows: 
•   Estimating parameter using Equation 6.2: the !"#!! node is for estimating the 
parameter. The prior for the parameter is a!~! "#$%&'! 0,1 , and the posterior 
probability computes after entering observation into the network. 
•    Entering observation: the !"#!! node is the observation node for !"#!!.!The 
node is!~!!"#$%"&'(!,!). For example, in the case of Year → Number of 
meetings, ! is the number of meetings held during the particular year and ! is 
the probability of the meeting category.  
•    Calculating the probability of data: once the posterior parameter is estimated, 
then we calculate the probability of observing each data point conditional on that 
the model parameter learned. This is done by creating a node for each data point 
Establishing the Plausibility of Hypothetical Relations from Data 
 
100 
 
and entering fixed bins for < ! ! > ! , where ! is the data point. These 
prediction nodes for each data point are denoted as !"#$!!!, where ! = 1,… ,! 
and, !!is the number of data points. 
6.5   Selection of plausible relations – three 
variables                  
This section provides an example of the calculation using the fragment for the Number 
of meetings variable, which may depend on the variables Diagnosis and Year. 
For each possible model of the variables considered, the posterior probability of each of 
the prediction nodes !"#$!!!of the parameter models (i.e. the additional BNs 
constructed for learning parameters) are used to calculate the likelihood of all data given 
the model using Equation 6.3. The normalised score for each model indicates if the 
model is best for explaining the data.  
Table 6-3 presents the distribution of meeting categories for patients of each year of 
discussion and diagnosis combination. In particular, the dataset is for the variables of 
the fragment Number of meetings. We use the dataset to check each of the models 
presented in Figure 6.2. The model for the first hypothesis, ! !: Number of meetings is 
independent of Diagnosis and Year, corresponds to four parameters, of which three 
parameters are learned. This is because, the parameters for three out of the four meeting 
categories ensure sufficient data points to understand the model’s overall fit to the data. 
There are forty data points per meeting category (see Table 6.3), and thus, each 
parameter model has forty prediction nodes. In most cases, a prediction node has three 
fixed bins (see section 6.4), but when a recorded value is ‘0’ the node for this is set with 
bins! 0 1− !11 12− !"#!"!$%  to calculate the probability of the value. Table 6-4 
presents the probabilities of observing the data points conditional on that the model 
parameters are learned.  
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The model for the second hypothesis,!! !: Number of meetings is dependent on 
Diagnosis and Year, corresponds to (40×4) = 160 parameters, of which 120 parameters 
are learned. Each parameter model constructed for learning has only one data point. 
Figure 6-5 (c) illustrates the parameter model for learning the probability of a single 
meeting given that the discussion year is 2005 and the diagnosed cancer is benign 
pancreas. Appendix A.1 provides the posterior probability of the data point of this 
model along with the posterior probabilities of the data points of other parameter 
models constructed to assess this hypothesis. 
Further, the models for !!: Number of meetings is dependent on Year and !!: Number 
of meetings is dependent on Diagnosis correspond to 20 parameters and 32 parameters, 
respectively. Similar to the above, based on any combination of three meeting 
categories, the numbers of parameters select for learning !! is 15 and for learning !! is 
24. Figure 6-5 illustrates two of the parameter models constructed for these hypotheses. 
In particular, Figure 6-5 (a) illustrates that an observation regarding the year of 
discussion provides updated probability for receiving single meetings, which then 
remains constant over all data points to calculate the likelihood of each. Figure 6-5 (b) 
illustrates that an observation regarding the diagnosed cancer provides updated 
probability for single meetings which then remains constant over all data points to 
compute the posterior probability of each. The posterior probabilities of the data points 
from the all the parameter models of !! and !! can be found in Appendix A.1. 
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Table 6-3 Number of meetings and total data per meeting category for patients of each Year and 
Diagnosis combination 
Year Diagnosis Number of 
meetings 
Total  Year Diagnosis Number of 
meetings 
Total 
1 2 3  4 or 
more 
1 2 3 4 or 
more 
2005 BP 24 12 0 0 36  2007 ML 87 39 5 3 134 
BL 26 7 0 0 33 MGB 29 14 1 0 44 
BGB 18 6 0 0 24 Multiple 9 1 1 0 11 
MP 63 21 1 0 85 Unknown 23 8 2 0 33 
ML 60 31 4 0 95 2008 BP 34 19 2 0 55 
MGB 22 15 1 0 38 BL 29 11 0 0 40 
Multiple 3 3 0 0 6 BGB 10 9 1 0 20 
Unknown 35 8 0 0 43 MP 61 24 2 0 87 
2006 BP 13 3 0 0 16 ML 61 40 4 0 105 
BL 13 1 0 1 15 MGB 27 19 2 0 48 
BGB 7 6 0 0 13 Multiple 11 5 0 0 16 
MP 26 7 2 0 35 Unknown 46 23 3 1 73 
ML 44 10 3 0 57 2009 BP 10 0 1 0 11 
MGB 15 3 0 0 18 BL 3 2 1 0 6 
Multiple 3 0 0 0 3 BGB 8 2 0 0 10 
Unknown 19 2 0 0 21 MP 11 5 0 0 16 
2007 BP 25 10 0 0 35 ML 15 16 0 2 33 
BL 14 4 1 0 19 MGB 1 4 1 0 6 
BGB 19 4 0 0 23 Multiple 1 0 0 0 1 
MP 64 23 3 1 91 Unknown 15 6 0 0 21 
 
 
The normalised Bayesian score for each possible model for the variables Number of 
meetings, Year and Diagnosis is presented in Table 6-5. Results are obtained by 
calculating the joint probability of data using Equation 6.3 and normalising the values 
that are found for all competing models. As can be seen from the table, Bayesian score 
of the model that represents !! is higher than the other models, i.e. the model is the best 
for the data observed. 
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(a) A model constructed for learning a parameter for H3 
             (b)  A model constructed for learning a parameter for H4 
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Figure 6-5 Bayesian parameter learning networks for determining the best structure for the 
variables Number of meeting, Year and Diagnosis 
Table 6-4 Probabilities of data points obtained per learned parameter for !! of the Number of 
meetings fragment 
Year Diagnosis P(data point | Number of 
meetings = 
 Year Diagnosis P(data point| Number of 
meetings = 
1 2 3 1 2 3 
2005 BP 0.135 0.115 0.359  2007 ML 0.053 0.072 0.144 
BL 0.065 0.104 0.391 MGB 0.118 0.114 0.357 
BGB 0.138 0.169 0.504 Multiple 0.174 0.108 0.233 
MP 0.047 0.070 0.217 Unknown 0.144 0.135 0.173 
ML 0.051 0.060 0.146 2008 BP 0.068 0.072 0.254 
MGB 0.056 0.048 0.367 BL 0.114 0.136 0.321 
Multiple 0.205 0.171 0.841 BGB 0.044 0.054 0.325 
Unknown 0.023 0.049 0.295 MP 0.082 0.090 0.254 
2006 BP 0.122 0.163 0.632 ML 0.009 0.011 0.163 
BL 0.072 0.038 0.650 MGB 0.028 0.033 0.237 
BGB 0.123 0.090 0.689 Multiple 0.208 0.204 0.632 
MP 0.109 0.084 0.183 Unknown 0.063 0.085 0.185 
ML 0.039 0.022 0.140 2009 BP 0.075 0.025 0.233 
MGB 0.082 0.121 0.597 BL 0.205 0.318 0.147 
Multiple 0.313 0.363 0.917 BGB 0.209 0.247 0.750 
Unknown 0.015 0.029 0.548 MP 0.208 0.204 0.632 
2007 BP 0.132 0.146 0.369 ML 0.004 0.008 0.391 
                (c) A model constructed for learning a parameter for H2 
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BL 0.175 0.164 0.318 MGB 0.015 0.052 0.147 
BGB 0.062 0.098 0.518 Multiple 0.677 0.713 0.972 
MP 0.079 0.072 0.213 Unknown 0.177 0.188 0.548 
 
The method is applied in the same way to each of the remaining two fragments of three 
variables to select the best models among those that are possible; under each possible 
structure, a BN model constructs for each considered parameter. After estimating the 
parameter from data, the posterior probability of each corresponding data point is 
computed and finally, a Bayesian score from the joint probability of data is used to 
determine the best combination of relations for the variables considered. More 
calculation details regarding the hypotheses of the variables appeared in these fragments 
can be found in Appendix A.2 and in Appendix A.3. 
The normalised Bayesian score for each possible model for the variables of the above 
three fragments is presented in Table 6-5. As can be seen from the table, the learning 
method generates a higher score for !! under all three fragments. Since a higher score 
means stronger evidence in supporting the corresponding structure for the considered 
data, we can conclude that each of the three variables: Number of meetings, Organ and 
Type is dependent on both the parents Age and Year. 
Table 6-5 Joint probability and score per hypothesis per fragment 
   Outcome 
 
 
Hypothesis 
Number of meetings Organ Type 
Joint 
probability 
Score Joint 
probability 
Score Joint 
probability 
Score 
!! 
1.2829E-105 5.47388E-16 
1.2236E-
101 
7.08647E-
12 
6.7281E-
123 1.25859E-52 !! 
2.34372E-90 0.999999953 1.7267E-90 0.99999655 
5.34574E-
71 0.999999868 !! 
1.10872E-97 4.73059E-08 
5.89354E-
96 
3.41316E-
06 
7.05914E-
78 1.32052E-07 !! 
2.4982E-100 1.06591E-10 
6.32575E-
98 
3.66347E-
08 
5.5023E-
114 1.02928E-43 
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6.6   Selection of plausible relations – five 
variables 
The fragment of the MDT BN model for five variables is shown in Figure 6-6. With 
four hypothetical links, the expert has shown that Treatment depends on Age, Year, 
Diagnosis and Number of meetings. The data for learning plausible relations are the 
number of patients for each treatment option under each combination of values of all 
four parents. There are sixteen competing hypotheses (as explained in section 6.3). 
Similar to the previous section, we make use of the data to learn the parameters for each 
of these sixteen models. 
Since the number of parameters required for! !: Treatment is independent of Year, 
Number of meetings, Diagnosis and Age, is seven, as above, six of them are only needed 
to learn in order to assess the hypothesis. An additional BN network is constructed for 
learning each parameter for the hypothesis! !; since this hypothesis has the fewest 
parameters it associates with more data points than any other additional BN constructed 
for learning a parameter for any other hypothesis. In general, there is a decrease in the 
number of data points related to a parameter which corresponds to a hypothesis that 
corresponds to a greater number of parents. Each of the 6720 parameters (i.e. a 
conditional probability of a state for one of the 1120 possible combinations of parents) 
for !!: Treatment is dependent on Year, Number of meetings, Diagnosis and Age, 
therefore, had only one data point in association.  
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Figure 6-6 Structure of the MDT BN model fragment for learning plausible relations between 
five model variables 
 
Unlike the case of learning a parameter for !!, where an observation to a BN relates to 
only one data point so the posterior probability of one data point derives at once, for 
learning a parameter for !!, an observation relates to 1120 data points. This creates 
complications in calculating the probabilities given the observation; the time and 
memory needed to calculate the posterior probabilities for all the data points is 
unattainable.  
Java and AgenaRisk API, Java application program interface, are applied in this study 
to (a) construct the parameter learning BNs, (b) enter observations into the BN from a 
data file, (c) propagate the BN, and (d) generate the posterior probability of each data 
point (e) save the probabilities in a data file. However, when applied to the no causes 
case, !!, for a five variable fragment we are unable to complete learning any parameter 
for! !; the allocated memory runs out before the process could complete.  
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To get around this problem I have deleted those combinations of parents for which the 
total data (i.e. the number of patients observed for all treatment options) is found to be 
zero, and learned the parameters using the remaining data. This makes no difference in 
learning and does not require making any approximation. In particular, 960 
combinations of parents have been deleted in total. 
The joint probabilities of data calculated for each of the sixteen hypotheses are very 
small value (very close to ‘0’). We therefore applied logarithmic (!"#10) 
transformations to the probabilities to bring the values closer to numbers that can be 
used to compute a normalised score for each hypothesis. In particular, four steps are 
followed to calculate a score for a hypothesis: 
•   The joint probability of data for each hypothesis is transformed by 
applying!!"#10. 
•   The !"#10 Bayes Factor (BF) is calculated using Equation 2.3 for the 
hypotheses. In each case, the hypothesis that is chosen is! !, as it has the highest 
log10 BF among all calculated values. 
•   We then remove !"#10 by applying !"#$%&'10 to each calculated BF. 
•   Finally, the BFs are normalised so that the sum of the BFs is equal to ‘1’. 
Table 6-6 summarises the scores of the sixteen hypotheses for the variables Treatment, 
Year, Number of meetings, Diagnosis and Age. Clearly, the method produces a higher 
score for !! than any other hypothesis, which shows a higher support about the 
structure from data. So considering the scores in Table 6-6, we obtain the highest 
evidence to conclude that Treatment is dependent on three parents: Year, Number of 
meetings, Diagnosis, but not four that the expert has thought. 
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Table 6-6 Normalised scores of the sixteen competing hypotheses one of which assumes to be the 
best in terms of the data 
Hypothesis Likelihood (in log10) BF BF (revised) Score !! -884.368 -222.263 5.455E-223 4.9016E-223 !! -733.794 -71.689 2.04752E-72 1.8398E-72 !! -662.105 0 1 0.898552375 !! -788.010 -125.905 1.244E-126 1.1178E-126 !! -673.525 -11.420 3.80258E-12 3.41682E-12 !! -705.348 -43.243 5.7107E-44 5.13136E-44 !! -848.134 -186.029 9.3535E-187 8.4046E-187 !! -665.496 -3.391 0.000406231 0.00036502 !! -832.845 -170.741 1.8171E-171 1.6328E-171 !!" -812.405 -150.300 5.0077E-151 4.4996E-151 !!! -668.310 -6.205 6.2341E-07 5.60167E-07 !!" -663.054 -0.949 0.112494328 0.101082045 !!" -867.836 -205.731 1.8589E-206 1.6704E-206 !!" -851.743 -189.638 2.3015E-190 2.068E-190 !!" -872.490 -210.385 4.1199E-211 3.7019E-211 !!" -676.489 -14.384 4.12934E-15 3.71043E-15 
 
6.7   Revised model structure 
The revised structure of the MDT BN model, which we constructed in Chapter 5 and 
presented in Figure 5-5, is shown in Figure 6-7. The definitional links, those presented 
with thicker links, of the original model represent deterministic relations between the 
model variables, so no further revision was made for these links. The learning method is 
applied on to four fragments of the model in each of which the variables remain 
connected with hypothetical links. In one of these fragments the revised structure turns 
out to be dissimilar than which the expert has initially assumed; according to the 
expert’s assumptions, Age is one of the four factors to have strong  influence on 
Treatment but learning from data does not provide enough evidence in support of a 
structure that considers this relation. In each of the remaining three fragments, the 
expert has assumed relations between variables appropriately. 
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Figure 6-7  Revised structure of the MDT BN after learning the data supported relations. 
6.8   Summary 
This chapter demonstrated how relationships between variables in an expert constructed 
Bayesian network model can be checked to establish their plausibility with respect to 
data. The method applied enabled us to derive the best structure for each effect variable 
of the expert model in terms of data. These established structures were then combined to 
create a full model structure. The results from the hypothesis tests reveal that the 
clinician was right about most of the links. In particular, the revised MDT BN model 
has one less link than those appeared in the expert model. The next chapter focuses on 
conditional dependencies among variables and assesses the quality of each link of the 
BN.
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Chapter 7 
Evaluating the Strength of 
Associations  
Following the steps described in Chapters 5 and 6, the MDT model is both causally 
coherent – with support from a domain expert – and statistically valid – with support 
from data. As a result, the MDT model provides a framework to analyse the MDT data. 
The aim of this chapter is to analyse and determine the strength each association, and 
show how to form and assess hypotheses of clinical interest. 
7.1   Impact of MDT meetings 
As described in Chapter 5, the MDT BN model represents an MDT process through 
which recommendations were provided to cancer patients in the HPB 
(HepatoPancreaticoBiliary) centre at the Barts and the London NHS Trust (BLT). We 
wish to use the model to gain information against the success of MDT meetings for 
making treatment recommendations. For example, we are interested to know whether 
the MDT meetings have become more efficient over time. 
The increased interest in a coordinated plan for the management of cancer patients has 
made MDT meetings popular in oncology. Many researchers have shown that the 
management of cancer patients through discussions in MDT meetings improves 
outcomes.  
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Gabel et al. [168] demonstrated that MDTs have improved patients’ satisfactions by 
decreasing the time from diagnosis to treatment. Burton et al. [173] have concluded that 
MDT discussion of staging with magnetic resonance imaging and following 
implementation of preoperative treatment have significantly reduced the rate of positive 
circumferential resection margins.  
For finding evidence of the benefit of a lung cancer MDT meeting, the authors in [174] 
have used Chi-square tests and t tests along with a logistic regression model. The 
authors in [154] have also used Chi-square test while analysing the decisions of MDT 
meetings to skin cancer patients in order to find evidence of benefit. Both studies have 
considered a P value < 0.05 to be statistically significant.  
We discussed the limitations of these measures (P-values and Confidence Intervals) of 
frequentist statistics in detail in Chapter 2, and instead propose a Bayesian approach to 
evaluate the impact of the MDT meetings. Specifically, we assess the strength of each 
relation of the MDT BN model. Overall, for each relation, firstly we frame hypotheses 
about the effect, secondly learn the conditional probabilities and compute Bayes 
Factors, and finally, analyse these values. Provided that appropriate hypotheses are 
chosen, this analysis can show the changes that have occurred in the operation of MDT 
for making treatment recommendations and whether these changes have improved the 
efficiency of the MDT process over the years covered by the data. 
7.2   Conditional probabilities from data 
In this section, we explain construction of the Bayesian network that is used (in Section 
7.4) to compute the Bayes Factors of hypotheses about the strength of relations. These 
relations are determined by the conditional probabilities that are the parameters of the 
BN MDT model. Each conditional probability is the probability of a state of a child 
variable given the state of its parents. The probabilities are calculated from data. For 
example, in order to compute the probability of a cancerous organ given the age group 
based on the link Age → Organ, we count the total number of cancerous organs for 
patients in the particular age group as shown in Table 7-1. Each value included in the 
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row ‘Total’ includes the total number of cancerous organs for patients in each of the 
seven age groups during the period of the study. 
Table 7-1 Counts of the cancerous organ for patients in the corresponding age group 
Organ                                                    Age 
Under 46 46 – 54 54 – 60 60 – 66 66 – 71 71 – 77 77+ 
Pancreas 74 92 85 87 84 73 81 
Liver 107 91 82 98 93 102 85 
Bile duct 21 21 24 34 35 40 35 
Gallbladder 9 2 11 14 15 16 15 
Total 211 206 202 233 227 231 216 
       
For each of the age groups in Table 7-1, there are four parameters. However, instead of 
just calculating the percentage of the patients in each category, we make use of 
multinomial distribution by constructing a multinomial BN model (Figure 7.1). The 
multinomial distribution is a generalisation of the binomial distribution. The binomial 
distribution gives the probability of each outcome in n independent trials of a two 
outcome process whereas the multinomial distribution gives the probability of each 
outcome in n independent trials of a process in which there are more than two 
outcomes. 
In Figure 7-1, each parameter of the model is depicted as a node and denoted as!!"#!!!, 
where ! = 1,… . ,! and ! is the number of parameters. For the purpose of this study, 
we consider the prior for each parameter as uniform. The posterior distribution of 
parameters is computed after entering observations into the model. The observation 
node for each parameter is denoted as!! "#!!!, where ! = 1,… . , (! − 1) and !  is the 
number of data points. We modelled the observation node for !"#!!! using the 
expression in Equation 7.1 and the observation nodes for other parameters using the 
expression in Equation 7.2. With these expressions the model assumes that the observed 
data for each parameter is taken as Binomial, which is known to be an appropriate 
underlying sampling distribution when the number of cases and the size of the 
population are available [176]. 
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where !! is the total data for the age group and !! is the remaining total data at position !!,!and ! = 2,…… ,! − 1. Each node for total data is denoted as  !"#!!!! , where ! = 1,… . ,!!!and  !! is the number of data points.  
Having seen the observed data, the priors of the parameters update with a posterior 
distribution. A constraint is then used to set the sum of the probability over all the 
values equal to 1   (i.e. !!!!!! = 1).  
 
Figure 7-1  A multinomial BN model for estimating parameters from data 
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Figure 7-2 shows the underlying expressions used in the nodes of the multinomial 
model constructed to compute the posterior distribution of four parameters. 
 
Figure 7-2 Underlying expressions used for nodes in a multinomial BN model 
Table 7-2 provides the posterior probability (i.e. the mean of each distribution) for a 
cancerous organ given the age group of a patient. The complete conditional probability 
table for Organ is obtained from seven four-parameter multinomial BN models. 
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Table 7-2 Probability of each cancerous organ given the age group 
Organ                                                    Age 
Under 46 46 – 
54 
>54 – 
60 
>60 – 66 >66 – 71 >71 – 77 77+ 
Pancreas 0.348 0.441 0.417 0.371 0.368 0.316 0.373 
Liver 0.502 0.438 0.403 0.418 0.407 0.438 0.39 
Bile duct 0.106 0.107 0.121 0.148 0.156 0.174 0.164 
Gallbladder 0.044 0.014 0.058 0.063 0.069 0.072 0.073 
 
The remaining relations in the BN model correspond to the variables: (a) Age, (b) Year 
and (c) Diagnosis. Tables 7-3 to 7-5 provide calculated probabilities (posterior means) 
for the states of each variable that depends on one of these three variables in a 
corresponding link.  
Table 7-3 Probability of each cancer type given the age group 
From  To States Means 
   Under 46 46 – 54 >54 – 60 >60 – 66 >66 – 71 >71 – 77 77+ 
Age Type Benign 0.64 0.51 0.36 0.31 0.28 0.23 0.3 
Malignant 0.34 0.46 0.59 0.66 0.69 0.73 0.65 
Unknown 0.02 0.03 0.05 0.03 0.03 0.04 0.05 
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Table 7-4  Probabilities over the states of a) Organ, b) Type, c) Number of meetings and d) 
Treatment given year 
From To States Means 
 
 
 
 
 
 
 
 
 
 
 
Year 
 
  2005 2006 2007 2008 2009 
Organ Pancreas 0.37 0.34 0.36 0.43 0.29 
Liver 0.43 0.46 0.45 0.37 0.52 
Bile duct 0.14 0.14 0.14 0.15 0.09 
Gallbladder 0.06 0.06 0.05 0.05 0.1 
Type Benign 0.37 0.37 0.31 0.41 0.42 
Malignant 0.61 0.61 0.67 0.53 0.53 
Unknown 0.02 0.02 0.02 0.06 0.05 
Number of 
meetings 
1  0.69 0.77 0.69 0.62 0.6 
2 0.28 0.18 0.26 0.33 0.34 
3 0.02 0.03 0.04 0.04 0.04 
4 or more 0.01 0.02 0.01 0.01 0.02 
Treatment Chemotherapy  0.06 0.03 0.09 0.06 0.08 
Combination 0.21 0.16 0.11 0.09 0.05 
None  0.27 0.24 0.22 0.29 0.29 
Palliative 0.21 0.27 0.25 0.19 0.23 
Surgery 0.14 0.17 0.21 0.21 0.15 
Intervention radiology 0.04 0.04 0.03 0.04 0.02 
Watchful waiting 0.07 0.09 0.09 0.11 0.18 
 
 
Table 7-5 Probability of each meeting category given Diagnosis 
From To States Means 
 
Diagnosis 
 
 
 
BP BL BGB MP ML MGB Multiple Unknown 
Number of 
meetings 
1  0.67 0.73 0.67 0.71 0.62 0.6 0.68 0.71 
2 0.29 0.22 0.3 0.25 0.32 0.35 0.25 0.25 
3 0.03 0.03 0.01 0.03 0.04 0.04 0.05 0.03 
4 or 
More 
0.01 0.02 0.02 0.01 0.02 0.01 0.02 0.01 
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7.3   Impossible combination and learning 
conditional probabilities 
This section describes a variation of the method of Section 7.2 to allow for values that 
are known to be zero by definition (c.f. just observed to be zero). An example arises in 
the link Diagnosis → Treatment of the revised MDT BN, where some counts are always 
zero. For example, when a patient suffers with a benign cancer the MDT meetings never 
recommend chemotherapy as a treatment; the combination and palliative treatment 
options are also impossible. Table 7-6 states the number of patients with the particular 
treatment option for each particular diagnosis. An empty cell of the table indicates for 
that for the particular diagnosis no such treatment option was possible. Since such 
parameters are defined to be zero, we do not want to infer a small non-zero value. 
Moreover, by omitting these parameters and by computing a probability only when a 
treatment recommendation is a possible option, we increase the efficiency of the 
method.  
 
Table 7-6 Counts of the recommended treatments for patients in the corresponding diagnosis 
option 
From To States Means 
 
 
 
 
 
 
Diagnosis 
 
 
 
BP BL BGB MP ML MGB Multiple Unknown 
Treatment Chemotherapy  - - - 26 55 9 - 1 
Combination - - - 70 82 36 - 4 
None  53 68 21 38 60 11 5 127 
Palliative - - - 107 150 59 2 10 
Surgery 23 15 37 68 57 37 14 12 
Intervention 
radiology. 
10 9 - 2 20 2 - 2 
Watchful 
waiting 
65 20 16 3 0  5 35 
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 The steps required are: 
•   Consider the diagnostic options one at a time and determine how many 
parameters are there to learn; 
•   Construct a multinomial model for learning the parameters. The model 
corresponds to number of the parameters that we need to learn. 
•   Enter evidence into the models, and calculate the posterior probability 
distribution over each parameter given evidence using Bayes theorem. 
•   Return the mean value of the distribution of each parameter as its calculated 
posterior probability. 
Figures 7-3(a) and 7-3(b) depict the multinomial models constructed for learning 
parameters in relation to the diagnoses: benign pancreas (BP) and malignant pancreas 
(MP), respectively. The number of parameters of 7-3(a) is not same as the number of 
parameters of 7-3(b). In particular, for! "#$%&'"'! = !!", the probability is only 
computed for four possible treatment options, whereas, for! "#$%&'"' = ! " we can 
compute the probability for every treatment option. 
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Figure 7-3 (a)       A multinomial model for learning the probability of each treatment for benign 
pancreas 
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Figure 7-3 (b)      A multinomial model for learning the probability of each treatment for malignant 
pancreas
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Table 7-7 provides the posterior probability for each treatment option under each 
diagnosis. 
Table 7-7  Probabilities over the states of Treatment given diagnoses 
From To States Means 
D
ia
gn
os
is
 
 Tr
ea
tm
en
t 
 
BP BL BGB MP ML MGB Multiple Unknown 
Chemotherapy  - - - 0.08 0.13 0.06 - 0.01 
Combination - - - 0.22 0.19 0.23 - 0.03 
None  0.35 0.59 0.29 0.12 0.14 0.08 0.20 0.64 
Palliative - - - 0.34 0.34 0.37 0.10 0.06 
Surgery 0.15 0.14 0.49 0.21 0.15 0.24 0.50 0.07 
Intervention 
radiology. 
0.07 0.09 - 0.01 0.06 0.02 - 0.02 
Watchful 
waiting 
0.43 0.18 0.22 0.02 0.01  0.20 0.19 
7.4   Hypothesis tests for the strength of 
association 
The final step is to use the posterior probability distributions on the parameters of the 
MDT BN model, to perform hypothesis tests that provide information about the strength 
of each association. A hypothesis test considers two competing hypotheses and provides 
evidence to establish which is most plausible given the data.  
Figure 7-4 shows an example of one of the networks used to test the hypotheses of 
interest. It can be seen in the figure that this model combines two multinomial models, 
each of which corresponds to the parameter estimation part for a conditional probability 
of one of the variables. Given the probability distribution of this parameter inferred 
from data, we can assess the evidence for any hypothesized difference between the true 
value of the conditional probability for two different states of the variables. The test is 
conducted by linking the two multinomial models with a boolean variable as show in 
Figure 7-4. 
As an example, we can look for a possible difference in the probability of a particular 
cancerous organ given an older age group compared with the same probability given a 
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younger age group. The structure of a Bayesian network for evaluating this difference, 
for each of the organs for two age groups is shown in Figure 7-5, with four hypothesis 
variables. Each hypothesis test considers the following two hypotheses:  
•   !!!:!the probability of the organ is high for the old age group than the younger 
age group; 
•   !! the probability of the organ is not high for the old age group than the younger 
age group; 
We modelled the hypothesis node for the test using the expression in Equation 7.3. 
 
Having obtained the probability of each hypothesis for the hypothesis test, the Bayes 
Factor (BF) is calculated for the combination. A BF is the ratio of the probability of 
hypothesis,!!, being true given the data and the probability of the competing 
hypothesis, !!, being true given the same data [58]. The use of a BF also allows grading 
this according to the scale proposed by Jeffrey in [72] (see Section 2.3). 
Table 7-8 presents the results of the hypothesis tests used to analyse a possible 
difference in the probabilities of the different organs between the age groups under 46 
and 46-54 are compared. These results derive from the hypothesis nodes of the model 
depicted in Figure 7-5. The value of ‘Yes’ in a hypothesis node is the probability of ! ! 
which states that the probability of the corresponding organ is higher for the 46-54 age 
group than under 46 age group. The value of ‘No’ is the probability of the competing 
hypothesis !! which states that the probability of the organ is not higher for the 46-54 
age group than under 46 age group. In the Table 7-8, the row ‘BF’ provides the 
calculated ratio of the revised probabilities per hypothesis test. 
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Figure 7-4 A graphical representation of the model to test the hypotheses of interest. Left-hand 
and right-hand sides of the graph are identical, and each corresponds to parameter estimation part 
for the relevant link of the BN model depicted in Figure 6-7 
The results support evidence for an increase in the proportion of diseases of the 
pancreas for the 46-54 age group compared to the under 46 age group. In particular, the 
probability of ! ! is very low compared to the competing hypothesis ! ! for both the 
liver and the gallbladder, and the probability of ! ! is very close to ! ! for the bile duct. 
For the pancreas, the BF obtained is 22.45 and according to Jeffrey’s scale (see Table 2-
3) this is a strong evidence for !! that is, there is a strong evidence to suggest an 
increase in the proportion of diseases of the pancreas for the age groups considered 
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Figure 7-5  An example of actual Bayesian network to test the hypothesis of interest to the 
clinicians, e.g. if cancerous organs were high in an older age group (i.e., 46to54) than in a younger 
age group (i.e., under 46) 
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Table 7-8 Results per hypothesis test. A positive BF from a test indicates evidence to support an 
increase for the corresponding organ for the 46to54 age group compared with the under 46 age 
group 
  Organ 
Pancreas Liver  Bile duct Gallbladder !! 0.957 0.102 0.475 0.058 !! 0.043 0.898 0.525 0.942 !" 22.45 0.114 0.904 0.062 
 
Table 7-9 BF obtained for each organ from a hypothesis testing whether there is an increase for 
an older age group compared with a younger age group 
Compared 
to 
The probability is high 
for 
              BFs 
Pancreas Liver Bile 
duct 
Gallbladder 
Under 46  46-54 22.451 0.114 0.904 0.062 
>54-60 9.115 0.034 2.143 1.759 
>60-66 1.826 0.052 7.769 2.479 
>66-71  1.598 0.038 11.06 3.557 
>71-77  0.276 0.107 23.103 4.051 
77+  1.871 0.025 15.109 4.286 
46-54 >54-60  0.397 0.298 1.877 30.772 
>60-66  0.069 0.461 6.629 52.276 
>66-71  0.061 0.336 9.489 73.241 
>71-77  0.008 0.863 21.116 74.629 
77+ 0.079 0.199 13.172 89.129 
>54-60 >60-66  0.176 1.403 2.955 1.1 
>66-71  0.161 0.991 4.2 1.633 
>71-77  0.018 2.721 9.233 1.884 
77+ 0.194 0.609 5.778 1.949 
>60-66 >66-71  0.757 0.622 1.221 1.211 
>71-77  0.117 1.672 2.696 1.425 
77+ 0.881 0.375 1.718 1.465 
>66-71 >71-77  0.137 2.404 1.765 0.982 
77+ 0.995 0.526 1.155 1.002 
71-77 77+ 6.104 0.19 0.552 0.848 
  
A comparison of only two age groups is not a complete evaluation of the link Age → 
Organ given the available data; we therefore extended the hypothesis tests. We begin 
with the under 46 age group and selected each successive age group up to the >71-77 
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group to compare the probability of each organ for the particular age group with the 
probability of the organ for each older age group. 
Table 7-9 presents the complete set of BFs obtained from the tests evaluating the 
influence of Age on Organs. The results reveal that in most cases a change from a 
younger age group to a corresponding older age group has (a) reduces the proportion of 
diseases of the liver and pancreas and (b) increases the proportion of diseases of the bile 
duct and gallbladder, where a BF value lower than ‘1’ is evidence for a decrease and as 
above, a BF greater than ‘1’ is evidence for an increase.  
These changes are no consistent. Although reductions are more common, there are ten 
BFs giving evidence that cancers in the liver and pancreas have increased for older age 
groups. However, these BF values are considered as anecdotal evidence, revealing that 
no significant increase in the organ for the corresponding age groups. A similar 
conclusion also applies to three other BFs of the pancreas. But the BFs that resulted 
from the tests ‘>54-60’ > ‘under 46’ and ‘77+’ > ‘>71-77’ are considered as 
substantial evidence and the BF for the test ‘46-54’ > ‘under 46’ is considered as strong 
evidence to support the hypothesis.  
7.5   Impact of age on other factors 
In this section, and the following two sections, we give a more detailed analysis of the 
strength of some of the relation the MDT BN model. The main challenge of applying 
the technique described above is to present the information in a manner that can be 
understood by a domain expert. 
In the MDT BN model, the variable Age connects Organ and Type with two  links; we 
start, in this section, by investigating the impact of Age. In relation to Age →Organ, the 
question that clinicians in HPB Centre are interested in is whether changes have 
occurred in the cancerous organs according to the age of cancer patients (see Table 5.8), 
and in relation to Age →Type, the question of their interest is whether changes have 
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occurred in the types (Benign, Malignant and Unknown) according the age of cancer 
patients.  
Figure 7-6 shows a simple plot of the number of patients per cancerous organ for each 
of the seven age groups. Using the classical statistical approach, the clinicians mainly 
focus on these numbers to answer to a clinical question. However, the numbers of 
patients for two different age groups in any of the organs are not sufficient to estimate a 
difference in the particular organ between the two age groups; for a reliable estimate, 
both the values and the uncertainty must be considered, as our method does.  
 
 
Figure 7-6 Number of patients per cancerous organ for each of the seven age groups 
 
After calculating BFs (see Table 7-9) for the link Age →Organ, we analyse these values 
to assess: (1) changes that occur in each organ compared with other age groups in 
relation to a particular age group and (2) change that occurs in each organ for an older 
age group compared with younger age groups. Figure 7-7 (a) and (b) represent 
comparisons (1) and (2), respectively. In Figure 7-7 (a), we take the geometric mean of 
the BFs that result from the hypothesis tests, which each corresponds to one of the 
followings: 
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•   The probability estimated for the corresponding organ is higher for each 
successive older age group compared with the particular age group; 
•   The probability estimated for the corresponding organ is higher for the age group 
than each younger age group; 
To calculate the BF of interest, each hypothesis test for the youngest ‘under 46’ age 
group checks (a), whereas each hypothesis test for any other age group checks either (a) 
or (b). For example, if our interest is in combining the BFs for the 46-54 age group in 
the pancreas then the hypothesis tests we carry out are: ‘46-54’ > ‘under 46’ , ‘>54-60’ 
> ‘46-54’ , ‘>60-66’ > ‘46-54’ , ‘>66-71’ > ’46-54’ , ‘>71-77’ >  ‘46-54’ and ‘77+’ >  
‘46-54’.   
Figure 7-7 (b) includes the followings features: 
•   A BF value of 1 for the ‘under 46’ age group. This is because the youngest age 
group is the starting point for comparison situation (2) change that occurs in 
each organ for an older age group compared with younger age groups.  
•   The calculated BF of the test (i.e. ‘46-54’ > ‘under 46’) for 46-54 age group. 
The geometric mean of the BFs from 2 or more hypothesis tests for the remaining age 
groups. Each of these tests checks if the probability estimated for the corresponding 
organ is higher for the age group than for each younger age group. Thus, for the >54-60 
age group we calculate the geometric mean of the BFs from the hypothesis tests: ‘>54-
60’ > ‘under 46’, ‘>54-60’ > ‘46-54’ and ‘46-54’ > ‘under 46’. 
Both of the graphs (a) and (b) in Figure 7-7 represent the geometric mean of BFs in a 
log scale. A value greater than ‘1’ indicates evidence about an increase whereas a value 
which is lower than ‘1’ indicates evidence about a decrease. In particular, Figure 7-7 (a) 
demonstrates that gallbladder and bile duct cancers for older age groups are higher than 
younger age groups. In particular, considering the calculated means, we get the highest 
evidence (mean of BFs is 19.08) for concluding that gallbladder cancer for the older age 
groups is a significantly higher proportion than for the 46to54 age group. Also we get 
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an almost equal strength of evidence regarding a change when bile duct cancer for each 
age group is compared with others. Figure 7-7 (b) further demonstrates that the bile duct 
cancer is consistently higher for the older age groups than younger age groups. 
 
Figure 7-7 Geometric mean of BFs to assess a) changes that occur in each organ for other age 
groups in relation to a particular age group and b) a change that occurs in each organ for an older 
age group when compared with younger age groups 
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In comparison, Figure 7-6 makes it difficult to assess the strength of influence Age has 
on Organs, and consequently, to find if changes have occurred in the cancerous organs 
according to the age of cancer patients. But our analyses show that the link captures the  
impact between the variables properly. The liver and pancreas cancers decrease for 
older age groups (i.e. negatively influenced by the older age groups) whereas the bile 
duct and gallbladder cancers increase for older age groups (i.e. positively influenced by 
the older age groups). 
Similar to the Age → Organ, we follow the same procedure to assess two comparisons 
for Age → Type link: (1) changes that occur in each type of cancer for other age groups 
in relation to a particular age group and (2) a change that occurs in each type of cancer 
for an older age group when compared with all younger age groups. Figure 7-9 (a) and 
(b) represent comparisons (1) and (2), respectively. The BFs used for the analyses are 
presented in Appendix B.1. 
Figure 7-9 (a) demonstrates that the proportion of malignant cancer is higher in older 
age groups than younger age groups. In particular, we obtain the highest evidence (a 
geometric mean of 736.4) to conclude that the proportion of malignant cancer for the 
older age groups is significantly higher than under 46 age group. Also, the malignant 
cancer for the older age groups is higher than for the 46to54 age group (a geometric 
mean of 313.4). Evidence in relation to the proportion of benign cancer shows that this 
is lower for the older age groups than younger age groups.  
Figure 7-9 (b) demonstrates that apart from the age groups 46-54 and 77+ malignant 
cancer is significantly higher (a geometric mean of  >100) for each of the five other age 
groups compared to the corresponding younger age groups. In both graphs, we obtain 
only weak evidence for a change in an unknown cancer for older age groups compared 
to younger age groups. 
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Figure 7-8  Number of patients per cancer type for each of the seven age groups 
 
Figure 7-9 Geometric mean of BFs to assess a) changes that occur in each type of cancer for other 
age groups in relation to a particular age group and b) a change that occurs in each type of cancer 
for an older age group when compared with younger age groups 
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7.6   Efficiency in the MDT meetings with 
years 
This section checks if the MDT meetings are becoming efficient with years by assessing 
the link Year → Number of meetings. A number of hypothesis tests are carried out to 
find evidence about the changes in each number of meeting category, from one year to 
another. 
Table 7-10 presents the Bayes Factors from the hypothesis tests for meeting categories 1 
to 4 and more, for the five years considered. The BFs mostly indicate that single MDT 
meetings have decreased and multiple meetings (i.e. 2, 3, 4 or meetings) have increased 
over the years. However, even these results do not clearly provide an answer to the 
question “Given the data, how strong is the evidence that the proportion of multiple 
MDT meetings was greater for 2008 than all of the three earlier years?” To understand 
the change better, we do a further analysis on the results. The main point of interest is to 
know what change occurs in each meeting category for one year compared with the 
corresponding earlier years. 
 
Table 7-10 BFs (with two decimal places) that derive from the hypothesis tests for meeting 
categories 1 to 4 and more, for the five years considered 
Compared to The probability is high for               BFs 
1 2 3 4 or more 
2005 2006 18.78 0.03 2.59 4.41 
2007 0.67 0.36 3.74 6.48 
2008 0.03 7.58 3.69 1.68 
2009 0.04 3.85 2.65 18.89 
2006 2007 0.03 22.43 1.04 1.07 
2008 0.01 51.07 0.97 0.31 
2009 0.01 48.65 1.02 3.6 
2007 2008 0.04 22.7 0.78 0.22 
2009 0.05 8.19 0.88 3.47 
2008 2009 0.44 0.8 0.96 11.62 
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As before, the graph shows the following: 
•   A BF value of 1 for 2005, as this year is the starting point for investigating 
changes in the proportion of multiple meetings. 
•   The BF from the hypothesis test 06>05 for 2006. 
•   The geometric mean of the BFs results from the hypothesis tests for 2007 to 
2009. Each of the hypothesis tests checks if the probability estimated for the 
particular meeting category is (a) higher for the year than for each previous year 
or (b) higher for each previous year (when investigating about 2008, the years 
we look at are 2006 and 2007) than for of that year’s predecessors. Thus, for 
2008 we calculate the geometric mean of the BFs that accumulate from the 
hypothesis tests: 08>05, 08>06, 08>07, 07>06, 07>05 and 06>05. 
 
Figure 7-10 Geometric mean of BFs to assess efficiency in the MDT meetings with years 
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Figure 7-10 presents the meeting categories by four different lines. It illustrates that 
multiple meetings (twice in particular) increase for the later years (i.e. 2008 and 2009) 
compared with the previous years. For 2009, the evidence (mean of BFs = 4.36) was 
slightly stronger for more multiple meeting than for 2008 (mean of BFs = 3.55). The 
figure also illustrates that the proportion of other multiple meeting categories (thrice and 
four or more, in particular) increased for each later year when compared with the 
corresponding previous years. But the proportion of single meetings was only higher for 
2006 than 2005, otherwise decreasing a) for 2007 than 2006 and 2005, b) for 2008 than 
2007, 2008 and 2009 and c) for 2009 than all the previous years.   
Given a belief that the organisation of MDT meetings had become more efficient over 
the study years, the clinician (our expert) has assumed the data would show evidence of 
fewer multiple meetings for later years. However, the analysis shows that the changes in 
the proportion of the number of meeting categories were the opposite of that assumed 
by the clinician; however, the evidence for an increase in the proportion of multiple 
meetings is not strong. 
7.7   Impact of year on type, organ and 
treatment 
This section evaluates the other links from Year in the MDT BN model; apart from 
Number of meetings, the variable Year connects to Type, Organ and Treatment in the 
MDT BN model. The results derived from the hypothesis tests carried out to assess 
these links can be found in Appendix B.2. Figure 7-11 (a), (b) and (c) demonstrate 
changes to the values of the variables, as captured from the estimated probabilities, for a 
later year compared to the relevant previous years. Figure 7-11 (a) reveals that the 
proportion of malignant cancers was higher for 2007 than for 2006 and 2005 (mean of 
BFs = 5.68) but less for both 2008 and 2009 than for the previous years. In contrast, for 
both 2008 and 2009 the link has captured an increase in the proportion of benign cancer 
against the corresponding previous years. 
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It is an interesting fact that the findings regarding benign disease confirm the clinician’s 
expectation. Since the variable ‘year’ in the MDT BN represents changes from any 
unknown influential factors over time, the clinician view’s that progress has been made 
in detecting more cancers at a benign stage would be shown as an increase in the 
proportion of benign disease in later years. However, we note that the evidence 
suggesting an increasing proportion of benign disease in the later years (2008 and 2009) 
is very weak (geometric mean of relevant BFs is ≥!3). 
Figure 7-11 (b) reveals that up until 2007 the proportion of liver cancer for later year 
was more than the corresponding proportion for previous years. The proportion of liver 
cancer reduced for 2008 (mean of BFs = 0.26) and became high again for 2009 (mean 
of BFs = 1.23). As in the liver cancer, the derived evidence indicates that the proportion 
of gallbladder cancer for 2009 was higher than the previous years (mean of BFs = 1.92). 
In contrast, the evidence about bile duct and pancreas indicates a reduced proportion of 
these cancers for the later year. However, in each case there is only a week evidence to 
support these changes.    
In relation to the variable Treatment, analysis is performed to check the impact of Year 
on four outcomes: combination, chemotherapy, palliative and surgery. As illustrated in 
Figure 7-11 (c) for 2008 recommendations regarding palliative care and combination 
reduce compared to the previous three years (means of BFs are 0.42 and 0.02, 
respectively). The analysis also reveals that the MDTs are recommending more surgery 
to patients. Means of BFs that derive for 2007 and 2008 were 7.84 and 6.16, 
respectively. These findings examine the details of the link capturing association 
between Year and Treatment. Improvements within MDTs in higher years may have 
made it easier to recommend surgery as a treatment option than before.  
 
 
Evaluating Strong associations 
 
 
137 
 
 
Figure 7-11 Changes with years a) in Type, b) in Organ and c) in Treatment 
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7.8   Impact of diagnosis on the treatment and 
number of meetings 
This section evaluates the impact of Diagnosis on the Treatment and on the Number of 
meetings. The analyses performed basis the hypotheses on the expectations and 
clinically interests of the clinician. The hypothesis suggested by the clinician to explain 
the  link Diagnosis → Treatment is that the treatment surgery has been recommended 
more in situation when the diagnosis of cancer was complex (see Table 5-10). The 
hypothesis suggested for explaining the link Diagnosis → Number of meetings is that 
more multiple meetings were held in situation when the diagnosis of cancer was 
complex (Table 5-10). The aim of the analyses is therefore to find out whether the 
relations correspond to the suggestions made by the clinician.  
Similar to the other sections, the analysis is based on hypothesis tests. With each of 
these tests we check: 
•   In relation to the probability estimated for an outcome for one diagnosis, the 
probability of the same outcome is higher for each successive diagnostic 
category; 
•   The probability estimated for an outcome for one diagnosis is higher than the 
probability of the same outcome for each of the diagnostic categories that appear 
earlier; 
For benign pancreas, we mainly carry out a test to check (a), whereas for others a test 
checks either (a) or (b). The BFs resulted from these tests are provided in Appendix B.3. 
Figure 7-12 (a) and (b) present the geometric means of these BFs to show the strength 
of evidence for the differences that occurs in each outcome of the variables for each 
diagnosis category compared to others. 
In relation to the variable Treatment, we obtain the strongest evidence to show that the 
recommendation of surgery is less for unknown diagnosis than other known diagnosis 
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categories. The mean BFs of 329.95 and 36.6 also suggest that the surgery 
recommendations for other diagnosis categories were significantly higher than benign 
liver and benign pancreas, respectively. In relation to the variable Number of meetings, 
we obtain evidence to show that multiple meetings (twice and thrice in particular) for 
other known diagnosis categories are more likely than for benign liver (means 3.75 and 
1.5 for twice and thrice, respectively). Figure 7-12 (b) also reveals that single meetings 
are more likely for malignant diagnoses than benign liver. 
As before, these findings help to explore the characteristics of the impact of Diagnosis 
on the Treatment and Number of meetings variables captured in the MDT BN. 
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Figure 7-12     Evidence for a difference that occurs a) in surgery and b) in each meeting category 
for each diagnosis category compared to others 
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7.9   Using MDT findings for health care 
management 
Based on the findings from the above analyses it is possible to generate the following 
recommendations for the management: 
• The study showed how the age of a patient could help to understand which 
organ is likely to carry the infection and what is the likely stage of the disease. 
With the help of this information health professionals can refrain from arranging 
unnecessary tests while working towards diagnosis. 
• An earlier indication of the disease help health professionals to know about the 
treatment required, and thus allowing the management plan ahead the resources. 
For example, for a patient with a possibility of a benign cancer the possibility of 
receiving chemotherapy as a treatment recommendation is less but receiving a 
palliative care is more. 
• The study showed no evidence of an increase in more than 2 meetings per case 
with times. This suggests that while holding meetings twice to discuss a case is 
likely to show benefits in providing better treatment recommendations, the use 
of more meetings in most cases is not necessary. 
7.10 .   Summary 
We have presented a novel approach to evaluate the strength of a  link in a BN model, 
using data. The strength is measured using Bayes Factors comparing hypotheses about 
the true values of conditional probabilities of the variables connected in the model. By 
analysing the results of such tests in the MDT BN model, we are able to answer queries 
about the MDT process. For example, although the expert has assumed that the data will 
show a decrease in single meetings with years due to improvements with the MDT 
process, we do not find strong evidence to provide support for this. 
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Chapter 8 
A Method for Modelling Associations 
Chapters 5, 6 and 7 demonstrated how data and knowledge can be used together to 
construct a probabilistic model representing strong statistical associations between the 
domain factors. The method used is solely based on a health service case study. In this 
chapter we discuss how this can be applied in other domain and what would be required 
to test the generalizability of the method. The chapter is organised as follows: Section 
8.1 describes the modelling steps, along with the assumptions made and issues found. 
Section 8.2 provides details of a comprehensive tool based on the study method and the 
possible test for checking generalizability, Section 8.3 discusses some related research 
studies and Section 8.4 presents the summary. 
8.1  Modelling Associations 
This thesis considers both knowledge and data for modelling strong associations. In 
particular, three issues have been tackled. First, how knowledge and data can be used to 
identify if there exist associations between variables, secondly, how a complete 
structure of statistical associations can be build, and finally, how the strength of each 
association  modelled within the structure can be assessed to address queries regarding 
the problem domain.  Figure 8-1 depicts the process and the brief description about 
each step is as follows: 
•   Variables are selected from data. These variables represent the main factors for 
modelling a BN.  
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•   The knowledge of experts is used to determine four relation types, namely 1) 
illegal, 2) definitional, 3) impossible and 4) hypothetical, between the variables 
considered. This is done by presenting the variables in a tabulate form, such as 
Table 5-7, which allows experts to identify the relation types that may exist from 
one variable to others. 
•    The structure of a BN is modelled based on the relations identified in step 2.   
•    The fragments of the BN, each of which represents causal relationships assumed 
by the expert between a variable and its parents, are checked against data. For 
each fragment, we present hypotheses for the different combinations of parents. 
If the hypothesis corresponding to all the suggested parents receives the highest 
evidence of support from the data, the fragment remains the same; otherwise it is 
revised according to the data supported hypothesis 
•    Based on all revised fragments found from step 4, the structure of the initial BN 
is revised. The definitional fragments, in which the relations between the 
relevant variables are definitional, cannot be checked against data, so we do not 
make any change within these fragments.  
•    Multinomial models are created to learn the CPT for every relation that the 
expert considered as a causal relation and later received the support of existence 
from the data. The CPT contains the probabilities of the states of a variable 
under its parents’ states. We continue to learn probabilities for each state of the 
parent separately. Firstly, we count the frequency of occurrences of the states 
under the particular state from data, and then we create a multinomial model to 
calculate the probability distribution over the conditional probabilities by 
Bayesian inference. The process continues until all the states of the parent have 
been considered.   
•   The strength of each association is then assessed using data. Once the 
distributions over the conditional probabilities are calculated, these values 
needed to be used to evaluate the strength of associations between variables. We 
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therefore examine differences in probabilities between different states of the 
parent by means of a set of hypothesis tests, by combining two multinomial 
models. 
•    Further analyses on the data that are found the assessment are performed. In 
order to understand any existence of causality if there are changes in the ordered 
child variable due to changes in the parent variable. When the states of the child 
are not ordered, then some meaningful hypotheses are used to describe how the 
variable may influence on its child to investigate a change. 
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Figure 8-1   A flow chart of modelling associations 
No 
No 
1. Select required variables and their states from data 
2. Identify relationships from experts 
3. Combine identified relationships to construct initial BN structure 
4. Check support against data 
5b. Construct final BN structure 
7. Assess the relation to produce evidence of causal impact 
8a Investigate possible changes 
8b.Investigate changes due to causal 
influence of ordered parent 
Yes 
For every causal 
fragment 
Yes 
Received support? 
For every causal 
relation 
6. Create multinomial models to learn CPT 
Parent ordered? 
5a. Revise the fragment 
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8.1.1    Assumptions  
The steps mentioned earlier are used for modelling statistical associations under the 
following assumptions and limitations: 
•     Variables are identified in two ways: (a) by analysing the case study data and 
(b) by using the values of other variables. Therefore, it is not required to find 
variables from any related literature.  
•   The data used don’t have any missing value. We removed inconsistencies that 
existed at the beginning. This implies that the techniques used do not consider 
any imputation of missing values.  
•   The method of modelling association and making sense of causal influence 
depend on the use of continuous nodes. The AgenaRisk tool has the ability to 
properly incorporate continuous nodes and does not require using static 
discretisation [177]. It uses the dynamic discretisation method proposed in [79] 
which produces results with greater accuracy 
•    The BN constructed by taking account of the order in which the variables 
appeared in the problem domain. The term causality only used for the relations 
considered in the expert BN model. However, the direction of a relationship 
defined within the expert BN remains unchanged at every stage of the modelling 
process.  
•   In learning the structure of a causal fragment, !"#$%&'!(0, 1)!distribution is 
used as the prior belief on each parameter. This was to demonstrate that before 
the data is observed all the points of the parameters remains equally likely. 
However, one could also set a non-uniform distribution based on some prior 
values and this will not provide any restriction to learn the existence of a 
fragment by following the method used in this thesis.  
•   Similar to the structure, the prior belief on the parameters of each multinomial 
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model was modelled as! "#$%&'!(0, 1). A multinomial model could also be 
build by considering a non-uniform prior distribution for its parameters if 
experts have some values in mind. This selection will not restrict calculating 
probabilities after finding relevant observations. If the number of trials is 
observed from data, one will yet be able to calculate the posterior distribution of 
the parameters by means of Bayesian inference. The work in [178] demonstrated 
this. 
8.1.2    Modelling issues   
Input data source  
The domain expert’s knowledge and historical data containing details about the 
important factors and their values are the input data sources. 
Causal fragment 
The expert BN in Chapter 5 only modelled causal relations between variables. All 
causal assumptions regarding relation s and their directions are made based on the 
knowledge of the expert. The use of the data only explained if any association between 
the variables is plausible or not. 
The method used for learning the plausibility of relations within a causal fragment relies 
on manual calculation of the joint probability and normalised score. Figure 8-2 shows 
the time currently requires for calculating parameters from the observed data. As can be 
seen from the figure the time requires increases in a rapid manner with an increase in 
the number of observations per parameter. We can reduce this time by increasing the 
size of the RAM space of the machines used. 
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Figure 8-2   Time needed to calculate a parameter model 
 
Learning the strength of associations 
The method used for learning the strength of a plausible relation initially calculates the 
conditional probabilities for given states of the parent, and then the BFs by comparing 
the probabilities calculated. Similar to causal fragments the time requires for learning 
increases with the number of the states of the child variable. We analyse the BFs to 
bring evidence in support of a predefined hypothesis. The user must have the expertise 
to define a meaningful hypothesis. 
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8.2   Outline of a comprehensive tool 
In this section, we illustrate how the method proposed in this study can be applied to 
assess the quality of food in the food industry by an inspector. For an input dataset a set 
of variables will be identified as important variables by the tool implementing the 
method. The structure of the causal BN based on the knowledge of the inspector is 
shown in Figure 8-3(a). To construct this model the inspector enters details about the 
causal direction between 
• Season and E Coli 
• Season and Level of danger 
• E Coli and Level of danger 
• Level of danger and Food quality 
• Packing and Level of danger 
• Packing and E Coli 
The final model in Figure 8-3 (a) shows no association between Packing and E Coli 
after investigating the causal fragment Season      E Coli        Packing, and no 
association between Packing and Level of danger.  
Figure 8-3 (b) illustrates how the tool assess the strength of each relation of the final BN 
model. At this stage, the instructor provides the counts of the states of the child 
variables for the states of parents as an input data. The output is a set of Bayes Factors 
(BFs) each of which calculates from a joint multinomial model. Constructions of these 
auxiliary BNs stay hidden. 
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Figure 8-3  (a)    How to construct a BN structure using knowledge and data 
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Figure 8-3 (b)      How to evaluate the strength of a relation and address relevant queries  
The clinician can also analyse the produced BFs to obtain meaningful information about 
the domain. It is believed that an ordered variable often introduces changes in ordered 
way, and for other discrete variables this may not be the case.  
Table 8-1 BFs to assess changes in food quality according to the level of danger 
Compared 
to 
The probability 
is high for 
BFs of lipid disorder 
High Medium Low 
Low Medium 2.63 1.44 0.2 
High 7.94 4.03 1.2 
Medium High 7.17 0.73 0.8 
 
Counts Evaluating the strength 
E Coli Level 
of 
danger 
Season Food 
quality 
BFs 
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Let us assume that, in case of Level of danger!→  Food quality of the example model, 
the variable Level of danger is an ordered variable and thus, the quality of decreases as 
the level of danger changes from low to high. Figure 8-4 is an analysis of the BFs 
presented in Table 8-1. The graph is produced on a log scale by taking BFs (2.63, 7.94 
and 7.17) as inputs. The points on the graph are generated as follows: 
• !"#!Low → 1  
• !"#!Medium → 2.63  
• !"#!High! → !!ℎ!!!"#$"%&'(! "#$!!"!!"#! 2.63,7.94,7.17  
= 2.63×7.94×7.17! = 5.31 
 
 
Figure 8-4 Changes that occur in the quality of food with the level of danger 
If the states of the variable Level of danger are not in order, the variable does not 
necessarily indicate that the quality of food decreases gradually with the level of danger. 
Therefore, to analyse an impact we have to choose which assumption is best to follow. 
Consequently, Figure 8-5 is produced to check if for the higher probabilities of both the 
medium and high danger level, the probability of low food quality increases. Similar to 
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the earlier analysis, the graph is produce on a log scale by taking BFs (2.63, 7.94 and 
7.17) as inputs. The points on the graph are generated as follows: 
• !"#!!!"# → !ℎ!!!"#$"%&'(! "#$!!"!!"#!(2.63, 7.94)  
= 2.63×7.94! = 4.57 
• !!"! "#$%& → !ℎ!"!#$!%&'(! "#$!!"!!"#!(2,63, 7.17)  
= 2.63×7.17! = 4.34 
• !"#! "#ℎ! → !!ℎ!!!"#$"%&'(! "#$!!"!!"#!(7.94, 7.17) 
= 7.94×7.17! = 7.55 
        
Figure 8-5 Changes that occur in the low quality of food for the Medium and High danger levels 
compared to the Low level 
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8.3   Discussion and related research 
This section discusses some studies in which the authors have performed works that are 
similar to what we investigated for this thesis. The interest here is to show that the 
methodology used in this research could be applied to other studies.  
8.3.1    Medical case studies with related aims 
Ogunsakin et al. [179] tried to find out if age and blood cholesterol have any effect on 
the blood pressure. The study was based on data obtained from a teaching hospital. The 
type of the studied variables was categorical, and in order to test the level of 
significance between these variables they performed multiple regression analysis. After 
obtaining the regression equation the regression coefficient,!!!, is used to explain a 
possible variation such as if blood pressure increases as the age increases, thus 
indicating age is significant in the change of blood pressure.  
Tomera and Harakal [180] investigated what causes high blood pressure using animal 
data. Similar to the above study, they performed multivariate regression analysis to 
determine about relationships between blood pressure, hypertrophy, calcium and 
cadmium. They used the square of the correlation coefficient,!!!, the adjusted !! 
values, and the power statistics to test the existence of a relation and to understand how 
one variable influences another. 
Sultan and Rao [2] investigated the possible association between osteoporosis and 
periodontal disease. Their research was based on data from 80 postmenopausal women. 
They assessed the relationships between variables by Pearson’s correlation coefficient. 
The correlation coefficient, whether positive or negative, determines the degree or 
extent of association between the two variables; a large value suggests the relationship 
may be significant, whereas, a small value indicates that it might have appeared by 
chance. Table 8-2 displays the main results of their study.  
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Table 8-2 The results produced in [2] 
Variables Correlation with BMD 
r  p-value 
Bone mineral density (BMD) ...  ... 
Age -0.381  0.000 
Menopausal Age 0.116  0.307 
Years since menopause -0.417  0.000 
Body Mass Index 0.263  0.018 
Plaque index 0.027  0.814 
Gingival index -0.126  0.265 
Clinical attachment loss -0.009  0.937 
Alveolar bone loss -0.093  0.410 
Number of remaining teeth 0.047  0.047 
 
In [181] Rona et al. checked if two variables are significant at the 5% level. Based on 
the study data, containing blood pressure information of 9 years old children, they 
concluded that children who had a low birth weight had high systolic blood pressure ( ! < !0.05), but not diastolic blood pressure, and those who had a shorter length of 
gestation had high systolic blood pressure (! < !0.01). 
These studies have focused on evaluating relations using data derived in observational 
studies. They reported results to suggest about the existence of correlations between 
variables. However, the use P-values for assessing the strength of relations mean a 
decision maker will require making his own interpretation of the measures. The 
resulting decision can therefore have some error. 
In [2] the authors demonstrated that there was mildly negative correlation between Age 
and Bone mineral density (BMD) (r=-0.381), and the association was highly significant 
(p=0.000). However, this thesis demonstrates that a large number of hypotheses are 
required to test the existence of a relation between two variables in order to ensure a 
complete assessment of dependencies. Moreover, when there are many sources of 
evidence a conclusion regarding a query requires all of them to be considered during an 
analysis. 
Further, a multilevel regression model can only model one outcome variable but BNs 
are a suitable tool for modelling multiple outcomes. The methodology discussed in this 
thesis show that a BN can be used to understand various details of the problem domain.  
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8.3.2    Related approaches using Bayesian network 
modelling 
A BN is a suitable tool to represent causal associations of a domain. But it is not always 
the case that a relation has must represent causation between two variables; instead a 
relation can simply be an association. Many BNs are learnt directly from data using 
algorithms that do not distinguish causation from associations [182][183][184][116]. 
But there are algorithms (such as Pearl’s Inferred-Causation [41][185]) for discovering 
some causation from data when the direction of causal relations is known from some 
source other than data. 
Cooper and Yoo [185] used a mixer of experimental and observational data for learning 
a causal Bayesian network.  Their approach starts by constructing a hypothetical causal 
Bayesian network. They considered a set of assumptions such as the use of a) complete 
data without any missing data or hidden variable, b) all discrete variables, c) Dirchlet 
prior distribution of parameters and so on. Under these assumptions, a closed form 
Bayesian scoring metric is used to score causal networks that construct from 
experimental and observational data. 
In Dekker et al.’s [7] learning approach, the domain experts make a draft structure at 
first. In [186], domain experts identify constraints on the model, and then the model is 
modified by means of a cost function which determines the model’s differences from 
those constraints. Heckerman et al. [90] identify event equivalence and parameter 
modularity properties of metrics to simplify the use of expert knowledge, and apply a 
score metric and a search procedure to learn Bayesian networks from a combination of 
knowledge and statistical data. 
While these studies have considered expert judgments along with data to learn BNs for 
a domain, we have considered ways to use data to assess expert-suggested causal 
relations in a BN. Suppose there is a variable ! which is thought to be caused by three 
variables! , ! and!!. Using our methodology the domain expert can suggest that there 
are causal relations. We can further learn about the strength of these relations by doing 
Bayesian analysis. Although Bayesian analysis is used in algorithms for learning model 
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structures [187][188], Bayesian analysis to understand about the strength of relations in 
a Bayesian network is rare.  
This thesis presents techniques to tackle the above issue. Moreover, one can now model 
causal BN using knowledge and prove that the relations of the BN are plausible against 
data with confidence. Next, rather than scenario analysis of multiple binary nodes, 
Bayesian analysis can reveal information about two ordered or categorical nodes at any 
time.  
8.4   Summary 
This chapter explains the methodology proposed separately from the case study. It 
shows how the techniques can be combined into a novel data analysis method, and 
discusses the development of a new tool and its features to apply the modelling method 
in any domain.  Then the chapter shows that the use of multivariate regression model 
and P-values is inefficient to answer queries that arise from non-experimental data. In 
particular, results suggesting correlations and the strength of a relation are not sufficient 
for understanding causation which relies on the use of knowledge.  
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Chapter 9 
Conclusion 
This thesis has focused on the use of BNs for the analysis of evidence in health services 
derived from observational studies, currently considered the type of studies providing 
the weakest evidence. More specifically, it has proposed a novel way to use a BN model 
to combine the use of expert judgement and data from observational studies to answer 
queries.  
The research hypotheses with which the thesis started are reviewed in Section 9.1, with 
a summary and evaluation of how the thesis has demonstrated the hypotheses. The way 
forward and possible directions for the future research are outlined in Section 9.2. 
9.1   Review of the research hypotheses 
9.1.1    Hypothesis 1: the need for new methods 
It is important to propose a new method for analysing observational data and producing 
answer to queries. 
The use of expert judgment is indispensible for analysing certain types of clinical 
queries as an expert can identify the relations that model a problem domain. Bayesian 
networks give the flexibility to combine data with knowledge, which we have exploited 
to generate statistical evidence in the context of an expert-derived BN model. This 
thesis focuses on using BNs for the problem of clinical evidence derived from 
observational studies. 
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It is well known that experimental trials are not a possible design option to generate 
evidence for all clinical questions of interest. Even when a trial is possible, conducting a 
trial is sometime impractical since the time and cost required are often very high. So 
observational studies are conducted instead and researchers have commonly used P-
values and Confidence Intervals to assess the results produced. However, both the 
measures have been criticised for their improper use and inadequate interpretation of 
results.  
Bayesian inference can overcome many limitations of the above measures of the 
classical inference method. This thesis showed that the key advantages that make the 
Bayesian inference method particularly suitable for evaluating the strength of evidence 
found from observational data are that it can: 
•     Report on the probability of interest for evaluation of the strength of evidence. 
According to critics, the probability of data given the null hypothesis is not 
essential measure of evidence. Bayesian methods of statistical inference let us 
calculate what really is required and that is the probability of a hypothesis given 
data. 
•     Help to measure evidence and to determine the strength of the evidence. This is 
done by the use of Bayes Factors. A Bayes Factor, which is the ratio of the 
probabilities of two competing hypotheses, enables one to decide the strength of 
the evidence based on its magnitude. 
•     Support adequate interpretation by quantifying uncertainty. 
•    Permit inductive inference to assess cause-effect relations. By giving the 
probability for a hypothesis on the basis of the data Bayesian methods permit 
inductive inference, which are more appropriate for assessing cause-effect 
relations 
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A Bayesian network model can represent many types of relations and let us to generate 
evidence for situations which require many inferences to be performed. In addition, 
BNs can:  
•    Model multiple outcomes and therefore, can be used to model complex health 
care settings such as MDT meetings and waiting times, and derive evidence for 
its better management. 
•    Represent both discrete and continuous variables within a framework. 
•    Provide higher accuracy in incorporating continuous variables using dynamic 
discretisation algorithms. 
To understand the applications of BNs in the clinical and health service domain a 
survey was performed. This survey covered the types of application, the associated 
techniques of evaluation and their limitations. We found that: 
•   Many studies use train-test datasets for evaluation. 
•   The accuracy of predictions made by BNs has mostly been assessed using the 
states of one outcome. 
•    The performance of a BN has commonly measured using: area under the 
receiver operating characteristic curve (AUC), sensitivity, specificity, positive 
predictive value, negative predictive value, and HL statistics. 
•    Models fit to data have been explained using P-values. 
Overall, the survey showed that the existing techniques for using BNs in the clinical 
domain are not sufficient for analysing the strength of associations. This, together with 
the limitations of the measures of classical inference methods (Chapter 2) and the 
existing development methods of BNs (Chapters 3 and 6), confirms Hypothesis 1. 
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9.1.2    Hypotheses 2 & 3: The structure of a BN model 
from knowledge and data 
Data, if available, can demonstrate existence of associations in an expert constructed 
Bayesian Network model. 
Using both the knowledge of experts and data from an observational study we can form 
a BN to represent associations between its variables 
This thesis used a case study and data collected from meetings of a Multidisciplinary 
Team (MDT) that treats patient suffering with cancer or suspected to have cancer to 
introduce our research techniques. Initially, it constructed a causal BN by considering 
an expert’s assumptions about the existence and the direction of causal associations. 
We evaluated the expert-judged causal associations in the initial BN against data and 
used the results to revise the initial BN model. The algorithmic steps followed for this 
are: 
•   Considered each causal fragment of the expert constructed BN. 
•   Considered the relations between the fragment variables as a hypothesis. 
•   Used the available data for testing the hypothesis against all competing 
hypotheses. 
•    Revealed if two variables that thought to have a causal relation between them 
receive support of association from the data. 
•   Constructed a BN with both knowledge and data. 
Hence, Chapters 5 and 6 confirm Hypotheses 2 and 3.  
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9.1.3    Hypothesis 4: The strength of strong associations 
For the BN model we can assess the strength of each association. The results from this 
assessment can then help to address a relevant query with confidence. 
After evaluating the existence of each expert-derived relation, we then assess how 
strong this association is. The algorithmic steps followed for this are: 
•   Considered each strong association from the revised BN model. 
•   Determined the posterior distribution over the parameters of each strong 
association from data, using an auxiliary multinomial BN model. 
•   Performed hypothesis tests. 
•   Produced evidence about differences between the probabilities computed from 
the data. 
•   Demonstrated how these differences can be useful for decision-support. 
Hence, Chapter 7 confirms Hypothesis 4. 
9.1.4   Hypothesis 5: A method for analysing 
observational data  
It is possible to apply the above techniques to successfully analyse observational data in 
any domain  
Finally, the thesis presented a novel approach for analysing observational data by using 
knowledge and data. It: 
•    Combined the above evaluation techniques and presented the complete 
methodology for the analysis of data. 
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•    Sowed that the approach is not restricted to the domain of our case study but can 
be applied to successfully analyse relations in any domain. 
Hence, this part of the research (Chapter 8) confirms Hypothesis 5. 
9.2   Future work  
This research could be extended in the following ways: 
•  To extend the MDT model and collect more data for investigating how MDT 
meetings help patients after they receive treatments. 
•   Instead of keeping the direction of an expert’s judged relation unchanged 
throughout, it would be interesting to investigate if there is a possible change of 
the direction. 
•   The structure leaning technique proposed in this study depends on using a 
uniform prior on each parameter. It would be useful to investigate the technique 
by using a non-uniform distribution based on some prior values to demonstrate 
that this will not provide any restriction to learn the existence of a fragment by 
following the method used in this thesis. 
•   Develop a single software tool from the studied methods for modelling BNs 
from knowledge and data, and analysing observational data. 
•   To speed up inference in BNs using more efficient inference algorithms. 
•    To guide users by providing an interface that allows sequential selection of the 
steps depicted in Figure 8-1. 
•   To ensure database connectivity – so that the users can complete each modelling 
step using the relevant data file. 
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•    To automate calculation of joint probability of data and a Bayesian score – so 
that the users can find a complete structure without looking into detail.
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Appendix A  
Establishing plausible causal relations 
A.1 Plausible relations - number of meetings, 
year and diagnosis 
 
Table A-1 The posterior probability of each data point for each learned parameter of H2: 
Number of meetings is dependent on Diagnosis and Year 
Year Diagnosis P(data point | Number of 
meetings = 
  
Year 
Diagnosis P(data point| Number of 
meetings = 
1 2 3 1 2 3 
2005 BP 0.099 0.099 0.505  2007 ML 0.050 0.053 0.124 
BL 0.119 0.119 0.506 MGB 0.089 0.090 0.254 
BGB 0.131 0.131 0.509 Multiple 0.214 0.272 0.272 
MP 0.069 0.070 0.251 Unknown 0.105 0.113 0.195 
ML 0.059 0.061 0.139 2008 BP 0.078 0.079 0.191 
MGB 0.091 0.093 0.255 BL 0.099 0.099 0.505 
Multiple 0.231 0.231 0.538 BGB 0.126 0.126 0.261 
Unknown 0.109 0.109 0.505 MP 0.065 0.067 0.189 
2006 BP 0.176 0.176 0.514 ML 0.055 0.056 0.138 
BL 0.205 0.266 0.515 MGB 0.081 0.082 0.190 
BGB 0.157 0.157 0.517 Multiple 0.151 0.151 0.514 
MP 0.107 0.118 0.195 Unknown 0.067 0.070 0.159 
ML 0.088 0.097 0.161 2009 BP 0.271 0.521 0.272 
MGB 0.174 0.174 0.512 BL 0.231 0.244 0.292 
Multiple 0.571 0.570 0.570 BGB 0.217 0.217 0.523 
Unknown 0.200 0.200 0.510 MP 0.151 0.151 0.514 
2007 BP 0.104 0.105 0.506 ML 0.097 0.098 0.506 
BL 0.145 0.156 0.261 MGB 0.292 0.243 0.292 
 
 
 
186 
 
BGB 0.152 0.152 0.509 Multiple 0.666 0.666 0.666 
MP 0.064 0.067 0.158 Unknown 0.135 0.135 0.510 
 
 
Table A-2 The posterior probability of each data point for each learned parameter of H3: 
Number of meetings is dependent on Year  
Year Diagnosis P(data point | Number of 
meetings = 
 Year Diagnosis P(data point| Number of 
meetings = 
1 2 3 1 2 3 
2005 BP 0.124 0.112 0.512  2007 ML 0.041 0.054 0.151 
BL 0.084 0.103 0.540 MGB 0.108 0.092 0.319 
BGB 0.152 0.165 0.635 Multiple 0.189 0.136 0.267 
MP 0.063 0.068 0.302 Unknown 0.143 0.147 0.208 
ML 0.037 0.058 0.077 2008 BP 0.102 0.105 0.256 
MGB 0.043 0.050 0.333 BL 0.062 0.095 0.271 
Multiple 0.189 0.171 0.890 BGB 0.090 0.104 0.340 
Unknown 0.037 0.051 0.453 MP 0.036 0.045 0.221 
2006 BP 0.228 0.236 0.593 ML 0.047 0.051 0.171 
BL 0.204 0.167 0.612 MGB 0.074 0.081 0.248 
BGB 0.036 0.019 0.652 Multiple 0.183 0.202 0.584 
MP 0.120 0.147 0.195 Unknown 0.088 0.085 0.197 
ML 0.105 0.118 0.152 2009 BP 0.038 0.014 0.262 
MGB 0.205 0.230 0.558 BL 0.261 0.319 0.179 
Multiple 0.482 0.547 0.903 BGB 0.138 0.188 0.690 
Unknown 0.102 0.154 0.509 MP 0.167 0.192 0.562 
2007 BP 0.135 0.136 0.296 ML 0.033 0.039 0.331 
BL 0.182 0.185 0.341 MGB 0.035 0.090 0.179 
BGB 0.075 0.126 0.443 Multiple 0.613 0.660 0.962 
MP 0.079 0.083 0.203 Unknown 0.117 0.154 0.477 
 
Table A-3  The posterior probability of each data point for each learned parameter of H4: 
Number of meetings is dependent on Diagnosis 
Year Diagnosis P(data point | Number of 
meetings = 
 Year Diagnosis P(data point| Number of 
meetings = 
1 2 3 1 2 3 
2005 BP 0.120 0.110 0.428  2007 ML 0.057 0.052 0.154 
BL 0.132 0.145 0.463 MGB 0.092 0.100 0.297 
BGB 0.136 0.144 0.623 Multiple 0.212 0.162 0.279 
MP 0.078 0.086 0.220 Unknown 0.131 0.146 0.177 
ML 0.075 0.077 0.177 2008 BP 0.058 0.071 0.206 
MGB 0.109 0.107 0.318 BL 0.113 0.097 0.403 
Multiple 0.164 0.140 0.742 BGB 0.048 0.074 0.246 
Unknown 0.061 0.095 0.293 MP 0.079 0.078 0.233 
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2006 BP 0.136 0.158 0.670 ML 0.046 0.037 0.177 
BL 0.156 0.104 0.687 MGB 0.085 0.091 0.236 
BGB 0.119 0.109 0.763 Multiple 0.170 0.158 0.490 
MP 0.136 0.120 0.176 Unknown 0.030 0.046 0.171 
ML 0.011 0.009 0.192 2009 BP 0.089 0.027 0.207 
MGB 0.034 0.054 0.512 BL 0.136 0.268 0.132 
Multiple 0.381 0.422 0.856 BGB 0.213 0.224 0.809 
Unknown 0.037 0.064 0.531 MP 0.199 0.181 0.635 
2007 BP 0.128 0.133 0.437 ML 0.020 0.024 0.275 
BL 0.186 0.200 0.275 MGB 0.036 0.105 0.184 
BGB 0.075 0.085 0.634 Multiple 0.717 0.743 0.948 
MP 0.078 0.083 0.189 Unknown 0.178 0.166 0.531 
 
A.2 Plausible relations - organ, age and year 
 
Table A-4  The cancerous organs for patients corresponding to the age group and year 
combination 
Age Year P(data point | 
Organ = 
Total  Age Year P(data point | Organ 
= 
Total 
B
ile
 d
uc
t 
G
al
lb
la
dd
er
 
Li
ve
r 
B
ile
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uc
t 
G
al
lb
la
dd
er
 
Li
ve
r 
Under 
46 
2005 2 2 32 54 >60-66      
2006 3 1 8 22 2008 11 4 25 68 
2007 6 2 30 54 2009 2 2 4 12 
2008 9 2 32 69 >66-71 2005 12 3 30 67 
2009 1 2 5 12 2006 6 3 10 24 
46-54 2005 6 1 26 49 2007 5 4 16 49 
2006 4 0 6 22 2008 11 3 27 69 
2007 3 0 23 45 2009 1 2 10 18 
2008 8 1 27 75 >71-77 2005 8 5 15 44 
2009 0 0 9 15 2006 4 2 18 37 
>54-60 2005 10 1 17 50 2007 10 3 32 66 
2006 2 1 17 28 2008 14 5 24 62 
2007 7 4 24 57 2009 4 1 13 22 
2008 4 4 15 55 77+ 2005 5 5 18 44 
2009 1 1 9 12 2006 2 2 10 22 
>60-66 2005 9 3 21 62 2007 15 2 27 66 
2006 4 1 14 25 2008 13 4 25 71 
2007 8 4 34 66  2009 0 2 5 13 
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Table A-5 The posterior probability of each data point for each learned parameter of H1: Organ 
is independent of Age and Year 
Age Year P(data point | Organ =  Age Year P(data point | Organ = 
Bile 
duct 
Gallbladder Liver Bile 
duct 
Gallbladder Liver 
Under 
46 
2005 0.013 0.228 0.007 >60-66     
2006 0.238 0.365 0.141 2008 0.109 0.192 0.057 
2007 0.141 0.228 0.021 2009 0.283 0.111 0.187 
2008 0.135 0.164 0.081 >66-71 2005 0.081 0.210 0.092 
2009 0.322 0.111 0.226 2006 0.065 0.100 0.160 
46-54 2005 0.160 0.184 0.044 2007 0.137 0.146 0.040 
2006 0.182 0.298 0.058 2008 0.112 0.205 0.077 
2007 0.074 0.088 0.067 2009 0.199 0.183 0.107 
2008 0.105 0.070 0.044 >71-77 2005 0.110 0.059 0.060 
2009 0.109 0.436 0.088 2006 0.176 0.272 0.103 
>54-
60 
2005 0.068 0.178 0.050 2007 0.126 0.212 0.066 
2006 0.152 0.333 0.028 2008 0.023 0.124 0.080 
2007 0.147 0.173 0.103 2009 0.182 0.365 0.056 
2008 0.065 0.167 0.007 77+ 2005 0.164 0.059 0.114 
2009 0.322 0.349 0.021 2006 0.224 0.220 0.163 
>60-
66 
2005 0.137 0.219 0.036 2007 0.019 0.177 0.091 
2006 0.201 0.351 0.070 2008 0.069 0.194 0.040 
2007 0.134 0.190 0.039  2009 0.146 0.124 0.209 
 
 
Table A-6 The posterior probability of each data point for each learned parameter of H2: Organ 
is dependent on both Age and Year 
Age Year P(data point | Organ =  Age Year P(data point | Organ = 
Bile 
duct 
Gallbladder Liver Bile 
duct 
Gallbladder Liver 
Under 
46 
2005 0.191 0.191 0.077 >60-66     
2006 0.171 0.259 0.124 2008 0.092 0.141 0.070 
2007 0.119 0.191 0.077 2009 0.211 0.211 0.172 
2008 0.099 0.190 0.067 >66-71 2005 0.089 0.159 0.068 
2009 0.270 0.211 0.165 2006 0.131 0.169 0.116 
46-54 2005 0.121 0.254 0.080 2007 0.130 0.143 0.085 
2006 0.152 0.510 0.134 2008 0.091 0.159 0.069 
2007 0.162 0.504 0.084 2009 0.263 0.203 0.134 
2008 0.104 0.251 0.067 >71-77 2005 0.108 0.131 0.089 
2009 0.515 0.515 0.148 2006 0.145 0.194 0.092 
>54-
60 
2005 0.098 0.253 0.084 2007 0.095 0.160 0.069 
2006 0.196 0.257 0.108 2008 0.084 0.128 0.073 
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2007 0.112 0.142 0.075 2009 0.152 0.259 0.122 
2008 0.142 0.142 0.085 77+ 2005 0.131 0.131 0.085 
2009 0.270 0.270 0.185 2006 0.200 0.200 0.120 
>60-
66 
2005 0.099 0.160 0.075 2007 0.082 0.191 0.070 
2006 0.151 0.258 0.113 2008 0.085 0.141 0.069 
2007 0.105 0.141 0.068  2009 0.517 0.210 0.160 
 
 
Table A-7 The posterior probability of each data point for each learned parameter of H3: Organ 
is dependent of Age  
Age Year P(data point | Organ =  Age Year P(data point | Organ = 
Bile 
duct 
Gallbladder Liver Bile 
duct 
Gallbladder Liver 
Under 
46 
2005 0.067 0.237 0.052 >60-66     
2006 0.202 0.357 0.072 2008 0.109 0.175 0.064 
2007 0.147 0.237 0.079 2009 0.284 0.138 0.193 
2008 0.098 0.198 0.068 >66-71 2005 0.099 0.155 0.073 
2009 0.364 0.091 0.184 2006 0.094 0.146 0.154 
46-54 2005 0.143 0.305 0.055 2007 0.102 0.174 0.060 
2006 0.120 0.736 0.053 2008 0.113 0.149 0.082 
2007 0.153 0.552 0.075 2009 0.160 0.224 0.088 
2008 0.125 0.316 0.038 >71-77 2005 0.140 0.112 0.053 
2009 0.198 0.809 0.099 2006 0.109 0.238 0.106 
>54-
60 
2005 0.047 0.166 0.073 2007 0.108 0.149 0.071 
2006 0.189 0.310 0.020 2008 0.071 0.156 0.068 
2007 0.139 0.165 0.092 2009 0.205 0.319 0.067 
2008 0.103 0.162 0.020 77+ 2005 0.117 0.112 0.108 
2009 0.343 0.348 0.016 2006 0.172 0.255 0.138 
>60-
66 
2005 0.126 0.186 0.047 2007 0.052 0.103 0.084 
2006 0.199 0.319 0.063 2008 0.098 0.156 0.070 
2007 0.112 0.176 0.035  2009 0.103 0.177 0.215 
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Table A-8 The posterior probability of each data point for each learned parameter of H4: Organ 
is dependent of Year 
Age Year P(data point | Organ =  Age Year P(data point | Organ = 
Bile 
duct 
Gallbladder Liver Bile 
duct 
Gallbladder Liver 
Under 
46 
2005 0.014 0.215 0.009 >60-66     
2006 0.226 0.343 0.112 0.117 0.178 0.092 0.117 
2007 0.141 0.238 0.044 0.207 0.224 0.099 0.207 
2008 0.119 0.182 0.033 >66-71 0.085 0.195 0.086 0.085 
2009 0.362 0.224 0.165 0.074 0.118 0.140 0.074 
46-54 2005 0.149 0.178 0.044 0.140 0.125 0.022 0.140 
2006 0.179 0.275 0.041 0.118 0.205 0.087 0.118 
2007 0.083 0.116 0.091 0.305 0.262 0.167 0.305 
2008 0.081 0.092 0.086 >71-77 0.113 0.067 0.062 0.113 
2009 0.249 0.215 0.168 0.162 0.251 0.113 0.162 
>54-
60 
2005 0.075 0.172 0.053 0.117 0.209 0.084 0.117 
2006 0.145 0.305 0.051 0.039 0.110 0.094 0.039 
2007 0.143 0.150 0.084 0.097 0.233 0.134 0.097 
2008 0.048 0.151 0.037 77+ 0.153 0.067 0.110 0.153 
2009 0.362 0.356 0.079 0.212 0.227 0.158 0.212 
>60-
66 
2005 0.130 0.204 0.039 0.019 0.200 0.067 0.019 
2006 0.192 0.326 0.097 0.088 0.181 0.086 0.088 
2007 0.131 0.170 0.065  0.296 0.236 0.130 0.296 
 
A.3  Plausible relations - type, age and year  
Table A-9 The cancer severity stages for patients corresponding to the age group and year 
combination 
Age Year P(data point | Type 
= 
Total  Age Year P(data point | Type 
= 
Total 
Benign Malignant 
 
Benign Malignant 
Under 
46 
2005 35 19 54 >60-66     
2006 13 9 22 2008 29 36 68 
2007 33 21 54 2009 4 8 12 
2008 47 20 69 >66-71 2005 15 51 67 
2009 9 3 12 2006 8 15 24 
46-54 2005 20 29 49 2007 15 34 49 
2006 15 7 22 2008 20 47 69 
2007 18 27 45 2009 6 11 18 
2008 41 29 75 >71-77 2005 17 27 44 
2009 11 4 15 2006 10 27 37 
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>54-60 2005 16 33 50 2007 10 56 66 
2006 11 17 28 2008 12 45 62 
2007 21 34 57 2009 5 15 22 
2008 19 32 55 77+ 2005 18 25 44 
2009 5 6 12 2006 5 16 22 
>60-66 2005 18 42 62 2007 14 51 66 
2006 6 19 25 2008 23 41 71 
2007 14 51 66 2009 4 9 13 
 
Table A-10 The posterior probability of each data point for each learned parameter of H1: Type 
is independent Age and Year 
Age Year P(data point | Type =  Age Year P(data point | Type = 
Benign Malignant 
 
Benign Malignant 
Under 
46 
2005 3.42E-05 2.09E-04 >60-66    
2006 0.020 0.034 2008 0.063 0.048 
2007 2.51E-04 0.001 2009 0.228 0.212 
2008 3.83E-07 7.75E-05 >66-71 2005 0.005 0.003 
2009 0.008 0.013 2006 0.157 0.160 
46-54 2005 0.099 0.112 2007 0.077 0.049 
2006 0.003 0.005 2008 0.039 0.040 
2007 0.110 0.118 2009 0.184 0.188 
2008 0.001 1.40E-04 >71-77 2005 0.118 0.119 
2009 0.004 0.008 2006 0.063 0.038 
>54-60 2005 0.089 0.081 2007 1.29E-04 1.34E-05 
2006 0.147 0.151 2008 0.002 0.014 
2007 0.107 0.105 2009 0.070 0.131 
2008 0.102 0.102 77+ 2005 0.105 0.108 
2009 0.216 0.176 2006 0.070 0.087 
>60-66 2005 0.045 0.050 2007 0.003 0.002 
2006 0.069 0.045 2008 0.070 0.086 
2007 0.003 0.002 2009 0.207 0.184 
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Table A-11 The posterior probability of each data point for each learned parameter of H2: Type 
is dependent on Age and Year 
Age Year P(data point | Type =  Age Year P(data point | Type = 
Benign Malignant 
 
Benign Malignant 
Under 
46 
2005 0.078 0.079 >60-66    
2006 0.122 0.121 2008 0.068 0.068 
2007 0.078 0.078 2009 0.172 0.172 
2008 0.072 0.074 >66-71 2005 0.081 0.080 
2009 0.185 0.186 2006 0.122 0.118 
46-54 2005 0.080 0.081 2007 0.087 0.087 
2006 0.128 0.128 2008 0.074 0.072 
2007 0.085 0.085 2009 0.140 0.136 
2008 0.065 0.066 >71-77 2005 0.086 0.087 
2009 0.163 0.163 2006 0.103 0.103 
>54-60 2005 0.084 0.083 2007 0.095 0.095 
2006 0.109 0.108 2008 0.089 0.079 
2007 0.077 0.076 2009 0.142 0.128 
2008 0.079 0.076 77+ 2005 0.085 0.085 
2009 0.165 0.163 2006 0.142 0.134 
>60-66 2005 0.078 0.076 2007 0.084 0.082 
2006 0.130 0.130 2008 0.071 0.066 
2007 0.084 0.082 2009 0.169 0.168 
 
 
Table A-12 The posterior probability of each data point for each learned parameter of H3: Type 
is dependent on Age  
Age Year P(data point | Type =  Age Year P(data point | Type = 
Benign Malignant 
 
Benign Malignant 
Under 
46 
2005 0.100 0.099 >60-66    
2006 0.140 0.133 2008 0.017 0.010 
2007 0.086 0.080 2009 0.226 0.231 
2008 0.078 0.066 >66-71 2005 0.064 0.057 
2009 0.191 0.200 2006 0.141 0.124 
46-54 2005 0.046 0.030 2007 0.105 0.111 
2006 0.051 0.070 2008 0.090 0.087 
2007 0.045 0.029 2009 0.170 0.140 
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2008 0.067 0.040 >71-77 2005 0.015 0.032 
2009 0.051 0.068 2006 0.121 0.134 
>54-60 2005 0.095 0.080 2007 0.039 0.017 
2006 0.133 0.142 2008 0.088 0.098 
2007 0.094 0.093 2009 0.189 0.149 
2008 0.098 0.091 77+ 2005 0.040 0.060 
2009 0.203 0.171 2006 0.148 0.141 
>60-66 2005 0.094 0.094 2007 0.040 0.020 
2006 0.136 0.111 2008 0.079 0.041 
2007 0.034 0.027 2009 0.226 0.218 
 
Table A-13 The posterior probability of each data point for each learned parameter of H3: Type 
is dependent on Year 
Age Year P(data point | Type =  Age Year P(data point | Type = 
Benign Malignant 
 
Benign Malignant 
Under 
46 
2005 1.01E-04 3.62E-04 >60-66    
2006 0.027 0.033 2008 0.086 0.090 
2007 2.07E-05 3.36E-05 2009 0.187 0.156 
2008 3.30E-05 7.94E-05 >66-71 2005 0.005 0.006 
2009 0.023 0.039 2006 0.145 0.154 
46-54 2005 0.098 0.104 2007 0.115 0.113 
2006 0.004 0.006 2008 0.017 0.006 
2007 0.056 0.065 2009 0.139 0.148 
2008 0.007 0.006 >71-77 2005 0.114 0.115 
2009 0.016 0.029 2006 0.059 0.051 
>54-60 2005 0.083 0.088 2007 0.003 0.002 
2006 0.139 0.141 2008 0.000 0.002 
2007 0.070 0.047 2009 0.038 0.075 
2008 0.071 0.081 77+ 2005 0.104 0.098 
2009 0.215 0.206 2006 0.067 0.098 
>60-66 2005 0.043 0.060 2007 0.028 0.032 
2006 0.066 0.057 2008 0.038 0.069 
2007 0.028 0.032 2009 0.158 0.124 
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Appendix B 
 Evaluating the strength of relations 
B.1 Impact of age on cancer types 
Table B-1 Bayes Factors (BFs) to analyse the impact of Age on Type 
Compared to The probability 
is high for 
              BFs 
Benign Malignant Unknown 
Under 46  46-54 0.004 59.184 1.276 
>54-60 3.54E-05 471.524 2.984 
>60-66 2.43E-05 5040.888 1.338 
>66-71         4.09E-05 912.245 1.119 
>71-77  9.13E-06 1508.999 1.835 
77+  5.32E-05 836.898 4.223 
46-54 >54-60  0.004 63.898 2.177 
>60-66  3.09E-04 520.707 0.847 
>66-71  0.002 859.361 0.716 
>71-77  2.25E-04 1473.737 1.252 
77+ 3.24E-04 380.113 3.193 
>54-60 >60-66  0.140 7.984 0.341 
>66-71  0.055 21.063 0.272 
>71-77  0.005 123.453 0.507 
77+ 0.107 4.652 1.208 
>60-66 >66-71  0.394 2.132 0.688 
>71-77  0.047 9.449 1.229 
77+ 0.654 0.603 3.280 
>66-71 >71-77  0.140 3.450 1.625 
77+ 1.467 0.263 4.536 
71-77 77+ 9.885 0.053 2.174 
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B.2 Impact of year on type, organ and 
treatment 
Table B-2   BFs to analyse the impact of Year on Type 
Compared to The probability is high for               BFs 
Benign Malignant Unknown 
2005 2006 0.928 0.782 1.023 
2007 0.028 19.975 0.601 
2008 3.725 0.026 40.241 
2009 3.23 0.101 6.066 
2006 2007 0.06 11.712 0.522 
2008 2.558 0.06 20.099 
2009 2.623 0.138 4.479 
2007 2008 150.196 0.003 53.275 
2009 33.753 0.01 7.748 
2008 2009 1.263 0.829 0.452 
 
Table B-3  BFs to analyse the impact of Year on Organ 
Compared 
to 
The probability is high 
for 
              BFs 
Pancreas Bile 
duct 
Gallbladder Liver 
2005 2006 0.31 0.81 1.04 2.21 
2007 0.4 0.6 0.43 3.33 
2008 9.08 1.47 0.51 0.07 
2009 0.05 0.08 11.28 13.61 
2006 2007 1.34 0.7 0.4 0.98 
2008 20.04 1.45 0.46 0.03 
2009 0.19 0.11 7.31 4.29 
2007 2008 22.41 2.33 0.96 0.01 
2009 0.09 0.11 20.58 5.01 
2008 2009 0.01 0.05 19.16 92.95 
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Table B-4 BFs to analyse the impact of Year on Treatment 
Compared 
to 
The probability 
is high for 
              BFs 
Chemotherapy Combination Palliative Surgery 
2005 2006 0.065 0.095 11.610 3.375 
2007 7.168 9.03E-04 5.941 34.760 
2008 0.524 6.70E-04 0.300 33.856 
2009 2.626 3.47E-04 1.660 1.204 
2006 2007 97.639 0.045 0.362 4.118 
2008 7.944 0.015 0.022 4.059 
2009 21.477 0.002 0.257 0.424 
2007 2008 0.044 0.313 0.033 0.825 
2009 0.638 0.014 0.489 0.094 
2008 2009 3.698 0.032 3.657 0.094 
 
B.3 Impact of diagnosis on treatment and MDT 
meetings 
Table B-5  BFs to analyse the impact of Diagnosis on Surgery 
Compared to The probability is high for BFs 
Surgery 
BP BL 0.047 
BGB 1690.196 
MP 3395.095 
ML 98.949 
MGB 4865.029 
Multiple 1045.525 
Unknown 0.001 
BL BGB 24887.508 
MP 16250.131 
ML 1351.473 
MGB 67662.794 
Multiple 8252.610 
Unknown 0.030 
BGB MP 1.072 
ML 0.038 
MGB 11.355 
Multiple 3.149 
Unknown 1.05E-06 
MP ML 0.017 
MGB 14.098 
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Multiple 3.183 
Unknown 6.54E-06 
ML MGB 416.795 
Multiple 38.551 
Unknown 1.6E-05 
MGB Multiple 0.555 
Unknown 5.94E-06 
Multiple Unknown 1.23E-05 
 
Table B-6  BFs to analyse the impact of Diagnosis on Number of meetings 
Compared to The probability is high for               BFs 
1 2 3 4 or 
more 
BP BL 4.342 0.140 0.758 2.981 
BGB 0.699 1.103 0.671 1.633 
MP 2.422 0.306 1.018 1.115 
ML 0.134 2.795 2.365 2.730 
MGB 0.094 5.687 1.732 0.878 
Multiple 1.001 0.384 1.979 2.905 
Unknown 2.294 0.256 1.171 1.756 
BL BGB 0.177 6.315 0.781 0.522 
MP 0.403 2.811 1.271 0.274 
ML 0.018 31.481 3.016 0.613 
MGB 0.015 49.561 2.111 0.238 
Multiple 0.350 1.421 2.382 1.108 
Unknown 0.462 1.909 1.471 0.480 
BGB MP 2.821 0.276 1.447 0.549 
ML 0.252 1.842 3.199 1.369 
MGB 0.160 3.657 2.270 0.481 
Multiple 1.178 0.343 2.514 1.816 
Unknown 2.657 0.234 1.644 0.974 
MP ML 0.012 20.590 2.501 3.004 
MGB 0.013 35.741 1.705 0.684 
Multiple 0.562 0.712 1.991 2.996 
Unknown 0.979 0.628 1.058 1.684 
ML MGB 0.401 2.689 0.755 0.252 
Multiple 2.966 0.172 1.147 1.382 
Unknown 32.239 0.041 0.442 0.578 
MGB Multiple 4.214 0.096 1.233 3.461 
Unknown 37.625 0.023 0.574 2.078 
Multiple Unknown 1.493 0.996 0.461 0.434 
 
